<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN""http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html><head><title>Patent US5556772 - Polymerase compositions and uses thereof - Google Patents</title><script>(function(){(function(){function e(a){this.t={};this.tick=function(a,c,b){var d=void 0!=b?b:(new Date).getTime();this.t[a]=[d,c];if(void 0==b)try{window.console.timeStamp("CSI/"+a)}catch(e){}};this.tick("start",null,a)}var a;window.performance&&(a=window.performance.timing);var f=a?new e(a.responseStart):new e;window.jstiming={Timer:e,load:f};if(a){var c=a.navigationStart,d=a.responseStart;0<c&&d>=c&&(window.jstiming.srt=d-c)}if(a){var b=window.jstiming.load;0<c&&d>=c&&(b.tick("_wtsrt",void 0,c),b.tick("wtsrt_",
"_wtsrt",d),b.tick("tbsd_","wtsrt_"))}try{a=null,window.chrome&&window.chrome.csi&&(a=Math.floor(window.chrome.csi().pageT),b&&0<c&&(b.tick("_tbnd",void 0,window.chrome.csi().startE),b.tick("tbnd_","_tbnd",c))),null==a&&window.gtbExternal&&(a=window.gtbExternal.pageT()),null==a&&window.external&&(a=window.external.pageT,b&&0<c&&(b.tick("_tbnd",void 0,window.external.startE),b.tick("tbnd_","_tbnd",c))),a&&(window.jstiming.pt=a)}catch(g){}})();})();
</script><link rel="stylesheet" href="/patents/css/_8a2b04e7bf975d5171d8e4c0b6365c7a/kl_intl_patents_bundle.css" type="text/css" /><script src="/books/javascript/atb_8a2b04e7bf975d5171d8e4c0b6365c7a__en.js"></script><script>function googleTranslateElementInit() {new google.translate.TranslateElement({pageLanguage: "en",gaTrack: true,gaId: "UA-27188110-1",multilanguagePage: true});}</script><script src="//translate.google.com/translate_a/element.js?cb=googleTranslateElementInit"></script><meta name="DC.type" content="Patent"><meta name="DC.title" content="Polymerase compositions and uses thereof"><meta name="DC.contributor" content="Joseph A. Sorge" scheme="inventor"><meta name="DC.contributor" content="Rebecca L. Mullinax" scheme="inventor"><meta name="DC.contributor" content="Stratagene" scheme="assignee"><meta name="DC.date" content="1994-2-16" scheme="dateSubmitted"><meta name="DC.description" content="The subject invention provides novel compositions containing a mixture of (a) an enzyme that possesses substantial 3&#39;-5&#39; exonuclease activity (b) a DNA polymerase with less 3&#39;-5&#39; exonuclease activity than the enzyme with substantial 3&#39;-5&#39; exonuclease activity. Preferably, the DNA polymerase for inclusion in the compositions are DNA polymerases that substantially lack 3&#39;-5&#39; exonuclease activity. A preferred embodiment of the invention is a composition comprising the Taq DNA polymerase (isolated from Thermus aquaticus) and the Pfu DNA polymerase (isolated from Pyrococcus furiosus). Another aspect of the invention is to provide methods for synthesizing polynucleotides, typically DNA, using compositions comprising an enzyme that possesses substantial 3&#39;-5&#39; exonuclease activity and a DNA polymerase with less 3&#39;-5&#39; exonuclease activity than the enzymes possessing substantial 3&#39;-5&#39; exonuclease activity, preferably a DNA polymerase that substantially lacks 3&#39;-5&#39; exonuclease activity. Another aspect of the invention involves the use the subject method of polynucleotide synthesis to carry out the synthesis step in a polymerase chain reaction experiment. Yet another aspect of the invention is to provide kits for the synthesis of polynucleotides, wherein the kits comprise an enzyme that possesses substantial 3&#39;-5&#39; exonuclease activity and a DNA polymerase with less 3&#39;-5&#39; exonuclease activity than the enzyme possessing substantial 3&#39;-5&#39; exonuclease activity."><meta name="DC.date" content="1996-9-17" scheme="issued"><meta name="DC.relation" content="EP:0502589:A2" scheme="references"><meta name="DC.relation" content="US:5436149" scheme="references"><meta name="DC.relation" content="WO:1992009689:A1" scheme="references"><meta name="citation_reference" content="Clark, J. M. et al. &quot;Novel Blunt-end Addition Reactions Catalyzed by DNA Polymerase I of Escherichia Coli&quot;. Journal of Molecular Biology 198:123-127 (1987)."><meta name="citation_reference" content="Clark, J. M. et al. Novel Blunt end Addition Reactions Catalyzed by DNA Polymerase I of Escherichia Coli . Journal of Molecular Biology 198:123 127 (1987)."><meta name="citation_reference" content="Clark, James M. &quot;Novel non-templated nucleotide addition reactions catalyzed by procaryotic and eucaryotic DNA polymerases&quot;. Nucleic Acids Research 16:9677-9686 (1988)."><meta name="citation_reference" content="Clark, James M. Novel non templated nucleotide addition reactions catalyzed by procaryotic and eucaryotic DNA polymerases . Nucleic Acids Research 16:9677 9686 (1988)."><meta name="citation_reference" content="Deng, Win Ping and Nickoloff, Jac A. &quot;Site-Directed Mutagenesis of Virtually Any Plasmid by Eliminating a Unique Site&quot;. Analytical Biochemistry 200:81-88 (1992)."><meta name="citation_reference" content="Deng, Win Ping and Nickoloff, Jac A. Site Directed Mutagenesis of Virtually Any Plasmid by Eliminating a Unique Site . Analytical Biochemistry 200:81 88 (1992)."><meta name="citation_reference" content="Hall, Len and Emery, David C. &quot;A rapid and efficient method for site-directed mutagenesis by PCR, using biotinylated universal primers and streptavidin-coated magnetic beads&quot;. Protein Engineering 4(5):601."><meta name="citation_reference" content="Hall, Len and Emery, David C. A rapid and efficient method for site directed mutagenesis by PCR, using biotinylated universal primers and streptavidin coated magnetic beads . Protein Engineering 4(5):601."><meta name="citation_reference" content="Hemsley, Anne et al. &quot;A simple method for site-directed mutagenesis using the polymerase using the polymerase chain reaction&quot;. Nucleic Acids Research 17(16):6545-6551 (1989)."><meta name="citation_reference" content="Hemsley, Anne et al. A simple method for site directed mutagenesis using the polymerase using the polymerase chain reaction . Nucleic Acids Research 17(16):6545 6551 (1989)."><meta name="citation_reference" content="Ho, Steffan N. et al. &quot;Site-directed mutagenesis by overlap extension using the polymerase chain reaction&quot;. Gene 77(1):51-59 (1989)."><meta name="citation_reference" content="Ho, Steffan N. et al. Site directed mutagenesis by overlap extension using the polymerase chain reaction . Gene 77(1):51 59 (1989)."><meta name="citation_reference" content="Hu, Gengxi. &quot;DNA Polymerase-Catalyzed Addition of Nontemplated Extra Nucleotides to the 3&#39; End of a DNA Fragment&quot;. DNA and Cell Biology 12(8):763-770 (1993)."><meta name="citation_reference" content="Hu, Gengxi. DNA Polymerase Catalyzed Addition of Nontemplated Extra Nucleotides to the 3 End of a DNA Fragment . DNA and Cell Biology 12(8):763 770 (1993)."><meta name="citation_reference" content="Hultman, Thomas et al. &quot;Solid phase in vitro mutagenesis using plasmid DNA template&quot;. Nucleic Acids Research 18(17):5107-5111 (1990)."><meta name="citation_reference" content="Hultman, Thomas et al. Solid phase in vitro mutagenesis using plasmid DNA template . Nucleic Acids Research 18(17):5107 5111 (1990)."><meta name="citation_reference" content="Jones, C. H. et al. &quot;DNA mutagenesis and recombination&quot;. Nature 344(6268):793-794 (1990)."><meta name="citation_reference" content="Jones, C. H. et al. DNA mutagenesis and recombination . Nature 344(6268):793 794 (1990)."><meta name="citation_reference" content="Jones, Douglas H. and Winistorfer, Stanley C. &quot;Recombinant Circle PCR and Recomination PCR for Site-Specific Mutagenesis Without PCR Product Purification&quot;. BioTechniques 12(4):528-533 (1992)."><meta name="citation_reference" content="Jones, Douglas H. and Winistorfer, Stanley C. Recombinant Circle PCR and Recomination PCR for Site Specific Mutagenesis Without PCR Product Purification . BioTechniques 12(4):528 533 (1992)."><meta name="citation_reference" content="Kunkel, Thomas A. &quot;Rapid and efficient site-specific mutagenesis without phenotypic selection&quot;. Proceedings of the National Academy of Sciences, USA 82:488-492 (1985)."><meta name="citation_reference" content="Kunkel, Thomas A. Rapid and efficient site specific mutagenesis without phenotypic selection . Proceedings of the National Academy of Sciences, USA 82:488 492 (1985)."><meta name="citation_reference" content="Landt, Olfert et al. &quot;A general method for rapid site-directed mutagenesis using the plymerase chain reaction&quot;. Gene 96:125-128 (1990)."><meta name="citation_reference" content="Landt, Olfert et al. A general method for rapid site directed mutagenesis using the plymerase chain reaction . Gene 96:125 128 (1990)."><meta name="citation_reference" content="Nassal, Michael and Rieger, Andrea. &quot;PCR-based site-directed mutagenesis using primers with mismatched 3&#39;-ends&quot;."><meta name="citation_reference" content="Nassal, Michael and Rieger, Andrea. PCR based site directed mutagenesis using primers with mismatched 3 ends ."><meta name="citation_reference" content="Nelson, Richard M. and Long, George L. &quot;A General Method of Site-Specific Mutagenesis Using a Modification of the Thermus aquaticus Polymerase Chain Reaction&quot;. Analytical Biochemistry 180:147-151 (1989)."><meta name="citation_reference" content="Nelson, Richard M. and Long, George L. A General Method of Site Specific Mutagenesis Using a Modification of the Thermus aquaticus Polymerase Chain Reaction . Analytical Biochemistry 180:147 151 (1989)."><meta name="citation_reference" content="Othler et al PCR Method &amp; Applications 2:51 59 (1992)."><meta name="citation_reference" content="Othler et al PCR Method &amp; Applications 2:51-59 (1992)."><meta name="citation_reference" content="Taylor, John W. et al. &quot;The rapid generation of oligonucleotide-directed mutations at high frequency using phosphorothioate-modified DNA&quot;. Nucleic Acids Research 13(24):8765-8775 (1985)."><meta name="citation_reference" content="Taylor, John W. et al. The rapid generation of oligonucleotide directed mutations at high frequency using phosphorothioate modified DNA . Nucleic Acids Research 13(24):8765 8775 (1985)."><meta name="citation_reference" content="Vallete, Francois et al. &quot;Construction of mutant and chimeric genes using the poymerase chain reaction&quot;, Nucleic Acids Research 17(2):723-733 (1989)."><meta name="citation_reference" content="Vallete, Francois et al. Construction of mutant and chimeric genes using the poymerase chain reaction , Nucleic Acids Research 17(2):723 733 (1989)."><meta name="citation_reference" content="Vandeyar, Mark A. et al. &quot;A simple and rapid method for the selection of oligodeoxynucletide-directed mutants&quot;. Gene 65:129-133 (1989)."><meta name="citation_reference" content="Vandeyar, Mark A. et al. A simple and rapid method for the selection of oligodeoxynucletide directed mutants . Gene 65:129 133 (1989)."><meta name="citation_reference" content="Watkins, Brynmor A. et al. &quot;A Rapid Method for Site-Specific Mutagenesis Using Larger Plasmids as Templates&quot;. BioTechniques 15(4):700-704 (1993)."><meta name="citation_reference" content="Watkins, Brynmor A. et al. A Rapid Method for Site Specific Mutagenesis Using Larger Plasmids as Templates . BioTechniques 15(4):700 704 (1993)."><meta name="citation_reference" content="Weiner, Michael P. et al. &quot;A method for the site-directed mono- and multi-mutagenesis of double-stranded DNA&quot;. Gene 126:35-41 (1993)."><meta name="citation_reference" content="Weiner, Michael P. et al. A method for the site directed mono and multi mutagenesis of double stranded DNA . Gene 126:35 41 (1993)."><meta name="citation_reference" content="Yao, Zhengbin et al. &quot;Site-directed Mutagenesis of Herpesvirus Glycoprotein Phosphorylation Sites by Recombination Polymerase Chain Reaction&quot;. PCR Methods and Applications 1(3):205-207 (1992)."><meta name="citation_reference" content="Yao, Zhengbin et al. Site directed Mutagenesis of Herpesvirus Glycoprotein Phosphorylation Sites by Recombination Polymerase Chain Reaction . PCR Methods and Applications 1(3):205 207 (1992)."><meta name="citation_reference" content="Zhu, Yu Sheng et al. &quot;The use of exonuclease III for polymerase chain reaction sterilization&quot;. Nucleic Acids Research 19(9):2511 (1991)."><meta name="citation_reference" content="Zhu, Yu Sheng et al. The use of exonuclease III for polymerase chain reaction sterilization . Nucleic Acids Research 19(9):2511 (1991)."><meta name="citation_patent_number" content="US:5556772"><meta name="citation_patent_application_number" content="US:08/197,791"><link rel="canonical" href="http://www.google.com/patents/US5556772"/><meta property="og:url" content="http://www.google.com/patents/US5556772"/><meta name="title" content="Patent US5556772 - Polymerase compositions and uses thereof"/><meta name="description" content="The subject invention provides novel compositions containing a mixture of (a) an enzyme that possesses substantial 3&#39;-5&#39; exonuclease activity (b) a DNA polymerase with less 3&#39;-5&#39; exonuclease activity than the enzyme with substantial 3&#39;-5&#39; exonuclease activity. Preferably, the DNA polymerase for inclusion in the compositions are DNA polymerases that substantially lack 3&#39;-5&#39; exonuclease activity. A preferred embodiment of the invention is a composition comprising the Taq DNA polymerase (isolated from Thermus aquaticus) and the Pfu DNA polymerase (isolated from Pyrococcus furiosus). Another aspect of the invention is to provide methods for synthesizing polynucleotides, typically DNA, using compositions comprising an enzyme that possesses substantial 3&#39;-5&#39; exonuclease activity and a DNA polymerase with less 3&#39;-5&#39; exonuclease activity than the enzymes possessing substantial 3&#39;-5&#39; exonuclease activity, preferably a DNA polymerase that substantially lacks 3&#39;-5&#39; exonuclease activity. Another aspect of the invention involves the use the subject method of polynucleotide synthesis to carry out the synthesis step in a polymerase chain reaction experiment. Yet another aspect of the invention is to provide kits for the synthesis of polynucleotides, wherein the kits comprise an enzyme that possesses substantial 3&#39;-5&#39; exonuclease activity and a DNA polymerase with less 3&#39;-5&#39; exonuclease activity than the enzyme possessing substantial 3&#39;-5&#39; exonuclease activity."/><meta property="og:title" content="Patent US5556772 - Polymerase compositions and uses thereof"/><meta property="og:type" content="book"/><meta property="og:site_name" content="Google Books"/><meta property="og:image" content="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><link rel="image_src" href="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><script>(function(){try{var aa=function(a,b,c,d){d=d||{};d._sn=["cfg",b,c].join(".");window.gbar.logger.ml(a,d)};var g=window.gbar=window.gbar||{},l=window.gbar.i=window.gbar.i||{},m={},n;function _tvn(a,b){var c=parseInt(a,10);return isNaN(c)?b:c}function _tvf(a,b){var c=parseFloat(a);return isNaN(c)?b:c}function _tvv(a){return!!a}function p(a,b,c){(c||g)[a]=b}g.bv={n:_tvn("2",0),r:"",f:".67.",e:"0",m:_tvn("0",1)};
function q(a,b,c){var d="on"+b;if(a.addEventListener)a.addEventListener(b,c,!1);else if(a.attachEvent)a.attachEvent(d,c);else{var f=a[d];a[d]=function(){var a=f.apply(this,arguments),b=c.apply(this,arguments);return void 0==a?b:void 0==b?a:b&&a}}}var s=function(a){return function(){return g.bv.m==a}},ba=s(1),ca=s(2);p("sb",ba);p("kn",ca);l.a=_tvv;l.b=_tvf;l.c=_tvn;l.i=aa;var da=window.gbar.i.i;var t,u,v,w;function ea(a){v=a}function fa(a){var b;if(b=v&&window.encodeURIComponent)b=a.href,b=!b.match(/^http[s]?:\/\/accounts\.google\.[^/]*\/ClearSID/i)&&!b.match(/^http[s]?:\/\/[^/]*\/accounts\/ClearSID/i);if(b=b&&encodeURIComponent(v()))a.href=a.href.replace(/([?&]continue=)[^&]*/,"$1"+b)}function ga(a){window.gApplication&&(a.href=window.gApplication.getTabUrl(a.href))}
function ha(a){var b=document.forms[0].q,c=window.encodeURIComponent&&b&&b.value,b=b&&b.placeholder;c&&c!=b&&(a.href=a.href.replace(/([?&])q=[^&]*|$/,function(a,b){return(b||"&")+"q="+encodeURIComponent(c)}))}n=l.a("")?ga:ha;
function x(a,b,c,d,f,e){var h=document.getElementById(a);if(h){var k=h.style;k.left=d?"auto":b+"px";k.right=d?b+"px":"auto";k.top=c+"px";k.visibility=u?"hidden":"visible";f&&e?(k.width=f+"px",k.height=e+"px"):(x(t,b,c,d,h.offsetWidth,h.offsetHeight),u=u?"":a)}}
var y=[],ia=function(a,b){y.push(b)},ja=function(a){a=a||window.event;var b=a.target||a.srcElement;a.cancelBubble=!0;null==t&&(a=document.createElement(Array.every||window.createPopup?"iframe":"div"),a.frameBorder="0",t=a.id="gbs",a.src="javascript:''",b.parentNode.appendChild(a),q(document,"click",z));var c=b,b=0;"gb3"!=c.className&&(c=c.parentNode);a=c.getAttribute("aria-owns")||"gbi";var d=c.offsetWidth,f=20<c.offsetTop?46:24;document.getElementById("tphdr")&&(f-=3);var e=!1;do b+=c.offsetLeft||
0;while(c=c.offsetParent);var c=(document.documentElement.clientWidth||document.body.clientWidth)-b-d,h,d=document.body,k=document.defaultView;k&&k.getComputedStyle?(d=k.getComputedStyle(d,""))&&(h=d.direction):h=d.currentStyle?d.currentStyle.direction:d.style.direction;h="rtl"==h;if("gbi"==a){for(d=0;k=y[d++];)k();A(null,window.navExtra);h&&(b=c,e=!0)}else h||(b=c,e=!0);u!=a&&z();x(a,b,f,e)},z=function(){u&&x(u,0,0)},A=function(a,b){var c,d=document.getElementById("gbi"),f=a;f||(f=d.firstChild);
for(;b&&(c=b.pop());){var e=d,h=c,k=f;w||(w="gb2");e.insertBefore(h,k).className=w}},ka=function(a,b,c){if((b=document.getElementById(b))&&a){a.className="gb4";var d=document.createElement("span");d.appendChild(a);d.appendChild(document.createTextNode(" | "));d.id=c;b.appendChild(d)}},la=function(){return document.getElementById("gb_70")},ma=function(){return!!u};p("qs",n);p("setContinueCb",ea);p("pc",fa);p("tg",ja);p("close",z);p("addLink",ka);p("almm",A);p("si",la);p("adh",ia);p("op",ma);var B=function(){},C=function(){},F=function(a){var b=new Image,c=D;b.onerror=b.onload=b.onabort=function(){try{delete E[c]}catch(a){}};E[c]=b;b.src=a;D=c+1},E=[],D=0;p("logger",{il:C,ml:B,log:F});var G=window.gbar.logger;var H={},na={},I=[],oa=l.b("0.1",.1),pa=l.a("1",!0),qa=function(a,b){I.push([a,b])},ra=function(a,b){H[a]=b},sa=function(a){return a in H},J={},K=function(a,b){J[a]||(J[a]=[]);J[a].push(b)},ta=function(a){K("m",a)},L=function(a,b){var c=document.createElement("script");c.src=a;c.async=pa;Math.random()<oa&&(c.onerror=function(){c.onerror=null;B(Error("Bundle load failed: name="+(b||"UNK")+" url="+a))});(document.getElementById("xjsc")||document.getElementsByTagName("body")[0]||
document.getElementsByTagName("head")[0]).appendChild(c)},N=function(a){for(var b=0,c;(c=I[b])&&c[0]!=a;++b);!c||c[1].l||c[1].s||(c[1].s=!0,M(2,a),c[1].url&&L(c[1].url,a),c[1].libs&&m.d&&m.d(c[1].libs))},O=function(a){K("gc",a)},P=null,ua=function(a){P=a},M=function(a,b,c){if(P){a={t:a,b:b};if(c)for(var d in c)a[d]=c[d];try{P(a)}catch(f){}}};p("mdc",H);p("mdi",na);p("bnc",I);p("qGC",O);p("qm",ta);p("qd",J);p("lb",N);p("mcf",ra);p("bcf",qa);p("aq",K);p("mdd","");p("has",sa);
p("trh",ua);p("tev",M);var Q=l.b("0.1",.001),R=0;
function _mlToken(a,b){try{if(1>R){R++;var c,d=a,f=b||{},e=encodeURIComponent,h=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&jexpid=",e("17483"),"&srcpg=",e("prop=22"),"&jsr=",Math.round(1/Q),"&ogev=",e("O6rtU-LcKvOssASEp4CIBw"),"&ogf=",g.bv.f,"&ogrp=",e("1"),"&ogv=",e("1407723702.0"),"&oggv="+e("es_plusone_gc_20140723.0_p0"),"&ogd=",e("com"),"&ogc=",e("NOR"),"&ogl=",e("en")];f._sn&&(f._sn="og."+
f._sn);for(var k in f)h.push("&"),h.push(e(k)),h.push("="),h.push(e(f[k]));h.push("&emsg=");h.push(e(d.name+":"+d.message));var r=h.join("");S(r)&&(r=r.substr(0,2E3));c=r;var Aa=window.gbar.logger._aem(a,c);F(Aa)}}catch(Na){}}var S=function(a){return 2E3<=a.length},va=function(a,b){return b};function T(a){B=a;p("_itl",S,G);p("_aem",va,G);p("ml",B,G);a={};H.er=a}l.a("")?T(function(a){throw a;}):l.a("1")&&Math.random()<Q&&T(_mlToken);I.push(["m",{url:"//ssl.gstatic.com/gb/js/scm_7385cc5883250b43a39405734c1bea59.js"}]);g.mcf("c",{});g.sg={c:""};if(l.a("1")){var wa=l.a("");I.push(["gc",{auto:wa,url:"//ssl.gstatic.com/gb/js/abc/gci_91f30755d6a6b787dcc2a4062e6e9824.js",libs:"googleapis.client:plusone:gapi.iframes"}]);var xa={version:"gci_91f30755d6a6b787dcc2a4062e6e9824.js",index:"",lang:"en"};H.gc=xa;var U=function(a){window.googleapis&&window.iframes?a&&a():(a&&O(a),N("gc"))};p("lGC",U);l.a("1")&&p("lPWF",U)};window.__PVT="";if(l.a("1")&&l.a("1")){var V=function(a){U(function(){K("pw",a);N("pw")})};p("lPW",V);I.push(["pw",{url:"//ssl.gstatic.com/gb/js/abc/pwm_45f73e4df07a0e388b0fa1f3d30e7280.js"}]);var W=[],ya=function(a){W[0]=a},za=function(a,b){var c=b||{};c._sn="pw";B(a,c)},Ba={signed:W,elog:za,base:"https://plusone.google.com/u/0",loadTime:(new Date).getTime()};H.pw=Ba;var X=function(a,b){for(var c=b.split("."),d=function(){var b=arguments;a(function(){for(var a=g,d=0,e=c.length-1;d<e;++d)a=a[c[d]];a[c[d]].apply(a,b)})},f=g,e=0,h=c.length-1;e<h;++e)f=
f[c[e]]=f[c[e]]||{};return f[c[e]]=d};X(V,"pw.clk");X(V,"pw.hvr");p("su",ya,g.pw)};function Ca(){function a(){for(var b;(b=e[h++])&&"m"!=b[0]&&!b[1].auto;);b&&(M(2,b[0]),b[1].url&&L(b[1].url,b[0]),b[1].libs&&m.d&&m.d(b[1].libs));h<e.length&&setTimeout(a,0)}function b(){0<f--?setTimeout(b,0):a()}var c=l.a("1"),d=l.a(""),f=3,e=I,h=0,k=window.gbarOnReady;if(k)try{k()}catch(r){da(r,"ml","or")}d?p("ldb",a):c?q(window,"load",b):b()}p("rdl",Ca);var Da={D:1,H:2,da:3,p:4,W:5,M:6,F:7,g:8,ha:9,U:10,L:11,T:12,S:13,N:14,Q:15,P:16,fa:17,w:18,O:19,ga:20,ea:21,u:22,G:23,ja:24,ka:25,ia:26,A:27,j:28,o:29,k:30,ca:31,Z:32,$:33,J:34,K:35,ba:36,aa:37,Y:38,B:39,R:40,v:41,X:42,V:43,h:48,C:49,I:500},Y=[1,2,3,4,5,6,9,10,11,13,14,28,29,30,34,35,37,38,39,40,41,42,43,48,49,500];var Z=l.b("0.001",1E-4),Ea=l.b("1",1),Fa=!1,Ga=!1;if(l.a("1")){var Ha=Math.random();Ha<=Z&&(Fa=!0);Ha<=Ea&&(Ga=!0)}var Ia=Da,$=null;function Ja(){var a=0,b=function(b,d){l.a(d)&&(a|=b)};b(1,"");b(2,"");b(4,"");b(8,"");return a}
function Ka(a,b){var c=Z,d=Fa,f;f=a;if(!$){$={};for(var e=0;e<Y.length;e++){var h=Y[e];$[h]=!0}}if(f=!!$[f])c=Ea,d=Ga;if(d){d=encodeURIComponent;g.rp?(f=g.rp(),f="-1"!=f?f:"1"):f="1";c=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&oge=",a,"&ogex=",d("17483"),"&ogev=",d("O6rtU-LcKvOssASEp4CIBw"),"&ogf=",g.bv.f,"&ogp=",d("22"),"&ogrp=",d(f),"&ogsr=",Math.round(1/c),"&ogv=",d("1407723702.0"),"&oggv="+
d("es_plusone_gc_20140723.0_p0"),"&ogd=",d("com"),"&ogl=",d("en"),"&ogc=",d("NOR"),"&ogus=",Ja()];if(b){"ogw"in b&&(c.push("&ogw="+b.ogw),delete b.ogw);var k;f=b;e=[];for(k in f)0!=e.length&&e.push(","),e.push(La(k)),e.push("."),e.push(La(f[k]));k=e.join("");""!=k&&(c.push("&ogad="),c.push(d(k)))}F(c.join(""))}}function La(a){"number"==typeof a&&(a+="");return"string"==typeof a?a.replace(".","%2E").replace(",","%2C"):a}C=Ka;p("il",C,G);var Ma={};H.il=Ma;setTimeout(function(){C(Ia.g)},0);}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var b=window.gbar.i.i;var c=window.gbar;var f=function(d){try{var a=document.getElementById("gbom");a&&d.appendChild(a.cloneNode(!0))}catch(e){b(e,"omas","aomc")}};c.aomc=f;}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var a=window.gbar;a.mcf("pm",{p:""});}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{window.gbar.rdl();}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
if (window['_OC_timingAction']) {window['_OC_timingAction']('patents_refpage');}</script><style>#gbar,#guser{font-size:13px;padding-top:1px !important;}#gbar{float:left;height:22px}#guser{padding-bottom:7px !important;text-align:right}.gbh,.gbd{border-top:1px solid #c9d7f1;font-size:1px}.gbh{height:0;position:absolute;top:24px;width:100%}#gbs,.gbm{background:#fff;left:0;position:absolute;text-align:left;visibility:hidden;z-index:1000}.gbm{border:1px solid;border-color:#c9d7f1 #36c #36c #a2bae7;z-index:1001}.gb1{margin-right:.5em}.gb1,.gb3{zoom:1}.gb2{display:block;padding:.2em .5em}.gb2,.gb3{text-decoration:none !important;border-bottom:none}a.gb1,a.gb4{text-decoration:underline !important}a.gb1,a.gb2,a.gb3,a.gb4{color:#00c !important}.gbi .gb3,.gbi .gb2,.gbi .gb4{color:#dd8e27 !important}.gbf .gb3,.gbf .gb2,.gbf .gb4{color:#900 !important}a.gb2:hover{background:#36c;color:#fff !important}#gbar .gbz0l{color:#000 !important;cursor:default;font-weight:bold;text-decoration:none !important}
#gbar { padding:.3em .6em !important;}</style></head><body  topmargin="3" marginheight="3"><div id=gbar><nobr><a onclick=gbar.qs(this);gbar.logger.il(1,{t:1}); class=gb1 id=gb_1 href="https://www.google.com/search?sa=N&tab=tw">Search</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:2}); class=gb1 id=gb_2 href="http://www.google.com/search?hl=en&tbm=isch&source=og&sa=N&tab=ti">Images</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:8}); class=gb1 id=gb_8 href="http://maps.google.com/maps?hl=en&sa=N&tab=tl">Maps</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:78}); class=gb1 id=gb_78 href="https://play.google.com/?hl=en&sa=N&tab=t8">Play</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:36}); class=gb1 id=gb_36 href="http://www.youtube.com/results?sa=N&tab=t1">YouTube</a> <a onclick=gbar.logger.il(1,{t:5}); class=gb1 id=gb_5 href="http://news.google.com/nwshp?hl=en&tab=tn">News</a> <a onclick=gbar.logger.il(1,{t:23}); class=gb1 id=gb_23 href="https://mail.google.com/mail/?tab=tm">Gmail</a> <a onclick=gbar.logger.il(1,{t:25}); class=gb1 id=gb_25 href="https://drive.google.com/?tab=to">Drive</a> <a class=gb3 href="http://www.google.com/intl/en/options/" onclick="this.blur();gbar.tg(event);return !1" aria-haspopup=true><u>More</u> <small>&#9660;</small></a><div class=gbm id=gbi><a onclick=gbar.logger.il(1,{t:24}); class=gb2 id=gb_24 href="https://www.google.com/calendar?tab=tc">Calendar</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:51}); class=gb2 id=gb_51 href="http://translate.google.com/?hl=en&sa=N&tab=tT">Translate</a><a onclick=gbar.logger.il(1,{t:17}); class=gb2 id=gb_17 href="http://www.google.com/mobile/?hl=en&tab=tD">Mobile</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:10}); class=gb2 id=gb_10 href="http://www.google.com/search?hl=en&tbo=u&tbm=bks&source=og&sa=N&tab=tp">Books</a><a onclick=gbar.logger.il(1,{t:212}); class=gb2 id=gb_212 href="https://wallet.google.com/manage/?tab=ta">Wallet</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:6}); class=gb2 id=gb_6 href="http://www.google.com/search?hl=en&tbo=u&tbm=shop&source=og&sa=N&tab=tf">Shopping</a><a onclick=gbar.logger.il(1,{t:30}); class=gb2 id=gb_30 href="http://www.blogger.com/?tab=tj">Blogger</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:27}); class=gb2 id=gb_27 href="http://www.google.com/finance?sa=N&tab=te">Finance</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:31}); class=gb2 id=gb_31 href="https://plus.google.com/photos?sa=N&tab=tq">Photos</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:12}); class=gb2 id=gb_12 href="http://www.google.com/search?hl=en&tbo=u&tbm=vid&source=og&sa=N&tab=tv">Videos</a><div class=gb2><div class=gbd></div></div><a onclick=gbar.logger.il(1,{t:66}); href="http://www.google.com/intl/en/options/" class=gb2>Even more &raquo;</a></div></nobr></div><div id=guser width=100%><nobr><span id=gbn class=gbi></span><span id=gbf class=gbf></span><span id=gbe></span><a target=_top id=gb_70 href="https://www.google.com/accounts/Login?service=&continue=http://www.google.com/patents%3Fhl%3Den&hl=en" class=gb4>Sign in</a><div style="display: none"><div class=gbm id=gbd5 aria-owner=gbg5><div class=gbmc><ol id=gbom class=gbmcc></ol></div></div></div></nobr></div><div class=gbh style=left:0></div><div class=gbh style=right:0></div><div role="alert" style="position: absolute; left: 0; right: 0;"><a href="http://www.google.com/patents/us5556772?hl=en&amp;output=html_text" title="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."><img border="0" src="http://www.google.com/images/cleardot.gif"alt="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."></a></div><div id="guser"><nobr></nobr></div><div style="clear:both;"></div><div id="gb-top-search-box" class="gb-top-search-box-small gb-reset"><table><tr><td class="logo"><a href="http://www.google.com/patents" class="logo-link"><img class="logo-img" src="/intl/en/images/logos/google_logo_41.png" alt="Go to Google Books Home" height="41"/></a></td><td><form action="http://www.google.com/search" name="f" id="vheadf" method="get"><span id="hf"></span><input type="hidden" name="tbm" value="pts"/><input type="hidden" name="tbo" value="1"/><input type="hidden" name="hl" value="en"/><table><tr><td><div class="inputs"><table><tr><td><div class="text-input"><input type="text" name="q" id="vheadq" class="text" maxlength="2048" size="31" value="" title="Search Patents" accesskey="s" autocomplete="off"/><script>window._OC_autoDir &&window._OC_autoDir('vheadq', 'tia-vheadq');</script></div></td><td><div class="submit-input"><input name="btnG" class="submit" type="submit" value=""/></div></td></tr></table></div></td><td class="col-ext-links"><div class="ext-links"><a href="http://www.google.com/advanced_patent_search">&lt;nobr&gt;Advanced Patent Search&lt;/nobr&gt;</a></div></td></tr></table></form></td></tr></table></div><div class="kd-appbar"><h2 class="kd-appname"><a href="/patents">Patents</a></h2><div class="kd-buttonbar left" id="left-toolbar-buttons"><a id="appbar-write-review-link" href=""></a><a id="appbar-view-print-sample-link" href=""></a><a id="appbar-view-ebook-sample-link" href=""></a><a id="appbar-patents-prior-art-finder-link" href="https://www.google.com/patents/related/US5556772"></a><a id="appbar-patents-discuss-this-link" href="http://www.google.com/url?id=805ABAABERAJ&amp;q=http://patents.stackexchange.com/redirect/google-patents%3Fpatent%3DUS5556772&amp;usg=AFQjCNHiqv2OImHV8fEL-x8LB6cqph4jCQ" data-is-grant="true"></a><a id="appbar-read-patent-link" href="//docs.google.com/viewer?url=patentimages.storage.googleapis.com/pdfs/US5556772.pdf"></a><a id="appbar-download-pdf-link" href="//patentimages.storage.googleapis.com/pdfs/US5556772.pdf"></a></div><div class="kd-buttonbar right" id="right-toolbar-buttons"></div></div><div id="books-microdata" itemscope=""itemtype="http://schema.org/Book"itemid="http://www.google.com/patents/US5556772" style="display:none"><span itemprop="description">The subject invention provides novel compositions containing a mixture of (a) an enzyme that possesses substantial 3&#39;-5&#39; exonuclease activity (b) a DNA polymerase with less 3&#39;-5&#39; exonuclease activity than the enzyme with substantial 3&#39;-5&#39; exonuclease activity. Preferably, the DNA polymerase for inclusion...</span><span itemprop="url">http://www.google.com/patents/US5556772?utm_source=gb-gplus-share</span><span class="main-title" itemprop="name">Patent US5556772 - Polymerase compositions and uses thereof</span><img itemprop="image" src="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"alt="Patent US5556772 - Polymerase compositions and uses thereof" title="Patent US5556772 - Polymerase compositions and uses thereof"></div><div style="display: none"><ol id="ofe-gear-menu-contents" class="gbmcc"><li class="gbe gbmtc"><a class="gbmt goog-menuitem-content" id="" href="http://www.google.com/advanced_patent_search">Advanced Patent Search</a></li></ol></div><table id="viewport_table" cellpadding="0" style="clear:both" cellspacing="0"><tr><td id="viewport_td"><div class=vertical_module_list_row><div id=intl_patents class=about_content><div id=intl_patents_v><table class="patent-bibdata"><tr><td class="patent-bibdata-heading">Publication number</td><td class="single-patent-bibdata">US5556772 A</td></tr><tr><td class="patent-bibdata-heading">Publication type</td><td class="single-patent-bibdata">Grant</td></tr><tr><td class="patent-bibdata-heading">Application number</td><td class="single-patent-bibdata">US 08/197,791</td></tr><tr><td class="patent-bibdata-heading">Publication date</td><td class="single-patent-bibdata">Sep 17, 1996</td></tr><tr><td class="patent-bibdata-heading">Filing date</td><td class="single-patent-bibdata">Feb 16, 1994</td></tr><tr><td class="patent-bibdata-heading">Priority date<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed."></span></td><td class="single-patent-bibdata">Dec 8, 1993</td></tr><tr><td class="patent-bibdata-heading">Fee status<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The fee status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status or dates listed."></span></td><td class="single-patent-bibdata">Paid</td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Also published as</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/US20060014205">US20060014205</a>, </span><span class="patent-bibdata-value"><a href="/patents/WO1995016028A1">WO1995016028A1</a></span></span></td></tr><tr class="patent-bibdata-list-row alternate-patent-number"><td class="patent-bibdata-heading">Publication number</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value">08197791, </span><span class="patent-bibdata-value">197791, </span><span class="patent-bibdata-value">US 5556772 A, </span><span class="patent-bibdata-value">US 5556772A, </span><span class="patent-bibdata-value">US-A-5556772, </span><span class="patent-bibdata-value">US5556772 A, </span><span class="patent-bibdata-value">US5556772A</span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Inventors</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Joseph+A.+Sorge%22">Joseph A. Sorge</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Rebecca+L.+Mullinax%22">Rebecca L. Mullinax</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Original Assignee</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=inassignee:%22Stratagene%22">Stratagene</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Export Citation</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/US5556772.bibtex">BiBTeX</a>, </span><span class="patent-bibdata-value"><a href="/patents/US5556772.enw">EndNote</a>, </span><span class="patent-bibdata-value"><a href="/patents/US5556772.ris">RefMan</a></span></span></td></tr><tr class="patent-internal-links"><td colspan=2><span class="patent-bibdata-value"><a href="#backward-citations">Patent Citations</a> (3),</span> <span class="patent-bibdata-value"><a href="#npl-citations">Non-Patent Citations</a> (44),</span> <span class="patent-bibdata-value"><a href="#forward-citations">Referenced by</a> (116),</span> <span class="patent-bibdata-value"><a href="#classifications">Classifications</a> (11),</span> <span class="patent-bibdata-value"><a href="#legal-events">Legal Events</a> (21)</span> </td></tr><tr><td colspan=2 class="patent-bibdata-external-link-spacer-top"></td></tr><tr class="patent-bibdata-external-link-spacer-bottom"></tr><tr><td colspan=2><span class="patent-bibdata-heading">External Links:&nbsp;</span><span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=805ABAABERAJ&q=http://patft.uspto.gov/netacgi/nph-Parser%3FSect2%3DPTO1%26Sect2%3DHITOFF%26p%3D1%26u%3D/netahtml/PTO/search-bool.html%26r%3D1%26f%3DG%26l%3D50%26d%3DPALL%26RefSrch%3Dyes%26Query%3DPN/5556772&usg=AFQjCNE5ZVuJsm_LgTVZKaAlY3wp88bydw">USPTO</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=805ABAABERAJ&q=http://assignments.uspto.gov/assignments/q%3Fdb%3Dpat%26pat%3D5556772&usg=AFQjCNEtCitA4mfTV7NtsdYoskYEVywkgg">USPTO Assignment</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=805ABAABERAJ&q=http://worldwide.espacenet.com/publicationDetails/biblio%3FCC%3DUS%26NR%3D5556772A%26KC%3DA%26FT%3DD&usg=AFQjCNFBfZ6JZUh7EM6WHut1LFIM2viRNg">Espacenet</a></span></span></td></tr><tr class="patent-bibdata-group-spacer"></tr></table><div class="number-and-title"><span class="patent-title"><invention-title mxw-id="PT54091304" lang="EN" load-source="patent-office">Polymerase compositions and uses thereof</invention-title></span><br><span class="patent-number">US 5556772 A</span></div><div class="patent-section patent-abstract-section"><div class="patent-section-header"><span class="patent-section-title">Abstract</span></div><div class="patent-text"><abstract mxw-id="PA37566954" lang="EN" load-source="patent-office"> <div class="abstract">The subject invention provides novel compositions containing a mixture of (a) an enzyme that possesses substantial 3'-5' exonuclease activity (b) a DNA polymerase with less 3'-5' exonuclease activity than the enzyme with substantial 3'-5' exonuclease activity. Preferably, the DNA polymerase for inclusion in the compositions are DNA polymerases that substantially lack 3'-5' exonuclease activity. A preferred embodiment of the invention is a composition comprising the Taq DNA polymerase (isolated from Thermus aquaticus) and the Pfu DNA polymerase (isolated from Pyrococcus furiosus). Another aspect of the invention is to provide methods for synthesizing polynucleotides, typically DNA, using compositions comprising an enzyme that possesses substantial 3'-5' exonuclease activity and a DNA polymerase with less 3'-5' exonuclease activity than the enzymes possessing substantial 3'-5' exonuclease activity, preferably a DNA polymerase that substantially lacks 3'-5' exonuclease activity. Another aspect of the invention involves the use the subject method of polynucleotide synthesis to carry out the synthesis step in a polymerase chain reaction experiment. Yet another aspect of the invention is to provide kits for the synthesis of polynucleotides, wherein the kits comprise an enzyme that possesses substantial 3'-5' exonuclease activity and a DNA polymerase with less 3'-5' exonuclease activity than the enzyme possessing substantial 3'-5' exonuclease activity.</div>
  </abstract></div></div><div class="patent-section patent-drawings-section"><div class="patent-section-header"><span class="patent-section-title">Images<span class="patent-section-count">(29)</span></span></div><div class="patent-drawings-body"><div class="patent-drawings-carousel"><div class="drawings"><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5556772-0.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5556772-0.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5556772-1.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5556772-1.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5556772-2.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5556772-2.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5556772-3.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5556772-3.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5556772-4.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5556772-4.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5556772-5.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5556772-5.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5556772-6.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5556772-6.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5556772-7.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5556772-7.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5556772-8.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5556772-8.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5556772-9.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5556772-9.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5556772-10.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5556772-10.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5556772-11.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5556772-11.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5556772-12.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5556772-12.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5556772-13.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5556772-13.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5556772-14.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5556772-14.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5556772-15.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5556772-15.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5556772-16.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5556772-16.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5556772-17.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5556772-17.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5556772-18.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5556772-18.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5556772-19.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5556772-19.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5556772-20.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5556772-20.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5556772-21.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5556772-21.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5556772-22.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5556772-22.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5556772-23.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5556772-23.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5556772-24.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5556772-24.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5556772-25.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5556772-25.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5556772-26.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5556772-26.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5556772-27.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5556772-27.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5556772-28.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5556772-28.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div></div></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img" alt="Previous page"src="/googlebooks/images/kennedy/page_left.png"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img" alt="Next page"src="/googlebooks/images/kennedy/page_right.png"width="21" height="21" /></div></div></div><div class="patent-post-drawings"></div><div class="patent-section patent-claims-section"><div class="patent-section-header"><span class="patent-section-title">Claims<span class="patent-section-count">(13)</span></span></div><div class="patent-text"><div mxw-id="PCLM5010800" lang="EN" load-source="patent-office" class="claims">
    <claim-statement>What is claimed is:</claim-statement> <div class="claim"> <div num="1" class="claim">
      <div class="claim-text">1. A kit for the synthesis of a polynucleotide, said kit comprising:<div class="claim-text">(a) a first DNA polymerase, wherein said first polymerase possesses 3'-5' exonuclease activity selected from the group consisting of Pyrococcus furiosus DNA polymerase, Thermotoga maritima DNA polymerase, Thermococcus litoralis DNA polymerase, and Pyrococcus GB-D DNA polymerase, and</div> <div class="claim-text">(b) a second DNA polymerase, wherein said second polymerase lacks 3'-5' exonuclease activity selected from the group consisting of Thermus aquaticus DNA polymerase, (exo-) Thermococcus litoralis DNA polymerase, (exo-) Pyrococcus furiosus DNA polymerase, and (exo-) Pyrococcus GB-D DNA polymerase.</div> </div>
    </div>
    </div> <div class="claim-dependent"> <div num="2" class="claim">
      <div class="claim-text">2. A kit according to claim 1, wherein said first and second DNA polymerases are thermostable.</div>
    </div>
    </div> <div class="claim"> <div num="3" class="claim">
      <div class="claim-text">3. A method of amplifying a polynucleotide sequence, said method comprising: the steps of mixing a composition, with a synthesis primer, and a synthesis template, said composition comprising<div class="claim-text">(a) a first DNA polymerase possessing 3'-5' exonuclease activity selected from the group consisting of Pyrococcus furiosus DNA polymerase, Thermotoga maritima DNA polymerase, Thermococcus litoralis DNA polymerase, and Pyrococcus GB-D DNA polymerase, and</div> <div class="claim-text">(b) a second DNA polymerase, wherein said polymerase lacks 3'-5' exonuclease activity selected from the group consisting of Thermus aquaticus DNA polymerase, (exo-) Thermococcus litoralis DNA polymerase, (exo-) Pyrococcus furiosus DNA polymerase, and (exo-) Pyrococcus GB-D DNA polymerase.</div> </div>
    </div>
    </div> <div class="claim-dependent"> <div num="4" class="claim">
      <div class="claim-text">4. A method according to claim 3 wherein said first and second DNA polymerases are thermostable.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="5" class="claim">
      <div class="claim-text">5. A method according to claim 3, wherein said first DNA polymerase is Pyrococcus furiosus DNA polymerase.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="6" class="claim">
      <div class="claim-text">6. A method according to claim 4, wherein said second DNA polymerase is Thermus aquaticus DNA polymerase.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="7" class="claim">
      <div class="claim-text">7. A method according to claim 5, wherein said second DNA polymerase is Thermus aquaticus DNA polymerase.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="8" class="claim">
      <div class="claim-text">8. A kit according to claim 2, wherein said first DNA polymerase is Pyrococcus furiosus DNA polymerase.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="9" class="claim">
      <div class="claim-text">9. A kit according to claim 2, wherein said second DNA polymerase is Thermus aquaticus DNA polymerase.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="10" class="claim">
      <div class="claim-text">10. A kit according to claim 8, wherein said second DNA polymerase is Thermus aquaticus DNA polymerase.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="11" class="claim">
      <div class="claim-text">11. A kit according to claim 1, said kit further comprising DNA primers.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="12" class="claim">
      <div class="claim-text">12. A kit according to claim 2, said kit further comprising DNA primers.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="13" class="claim">
      <div class="claim-text">13. A kit according to claim 10, said kit further comprising DNA primers.</div>
    </div>
  </div> </div></div></div><div class="patent-section patent-description-section"><div class="patent-section-header"><span class="patent-section-title">Description</span></div><div class="patent-text"><div mxw-id="PDES66828305" lang="EN" load-source="patent-office" class="description">
    <heading>RELATED APPLICATIONS</heading> <p>This application is a continuation-in-part of co-pending U.S. patent application 08/164,290 which was filed Dec. 8, 1993.</p>
    <heading>FIELD OF THE INVENTION</heading> <p>The present invention is related to the field of molecular biology, and more particularly, to polynucleotide synthesis.</p>
    <heading>BACKGROUND OF THE INVENTION</heading> <p>DNA polymerases catalyze the synthesis of DNA and can be found in all cells as well as being encoded in numerous viruses. Although all DNA polymerases possess 5'-3' DNA polymerase activity, DNA polymerases differ from one another in numerous other properties. For example, some enzymatic activities that are possessed by some DNA polymerases, but absent in other DNA polymerases include: double stranded DNA 5'-3' exonuclease activity, single-stranded DNA 3'-5' exonuclease activity, double-stranded 3'-5' DNA exonuclease activity, RNase H activity, reverse transcriptase activity, and the like. Additionally, different DNA polymerases may have different optimal pH and temperature ranges for activity. Furthermore, DNA polymerases may differ in the rate in which they catalyze DNA synthesis.</p>
    <p>Purified DNA polymerases have numerous uses in vitro. A detailed description of DNA polymerases, including methods for their isolation, can be found among other places, in DNA Replication 2nd edition, by Kornberg and Baker, W. H. Freeman &amp; Company, New York, N.Y. 1991. In vitro uses of DNA polymerases include, for example, the labeling and synthesis of hybridization probes, DNA sequencing, and DNA amplification. A DNA amplification method employing DNA polymerases that has been particularly useful is the polymerase chain reaction (PCR) technique. The technique of PCR is described in numerous publications, including, PCR: A Practical Approach, M. J. McPherson, et al., IRL Press (1991 ), PCR Protocols: A Guide to Methods and Applications, by Innis, et al., Academic Press (1990), and PCR Technology: Principals and Applications for DNA Amplification, H. A. Erlich, Stockton Press (1989). PCR is also described in many U.S. Patents, including U.S. Pat. Nos. 4,683,195; 4,683,202; 4,800,159; 4,965,188; 4,889,818; 5,075,216; 5,079,352; 5,104,792; 5,023,171; 5,091,310; and 5,066,584, which are hereby incorporated by reference. The PCR technique typically involves the step of denaturing a polynucleotide, followed by the step of annealing at least a pair of primer oligonucleotides to the denatured polynucleotide, i.e., hybridizing the primer to the denatured polynucleotide template. After the annealing step, an enzyme with polymerase activity catalyzes synthesis of a new polynucleotide strand that incorporates the primer oligonucleotide and uses the original denatured polynucleotide as a synthesis template.</p>
    <p>In many instances, a given DNA polymerase may fail to synthesize the desired polynucleotide product. These failures may be attributable to a number of reasons including such problems as template and primer base pair mismatches, lack of proofreading, insufficient rate of synthesis, high misincorporation rate, inability to transcribe GC or AT rich regions, lack of sufficient processivity (processivity refers to the length of synthesis product formed before the polymerase stops synthesis), etc. It is therefore of interest to provide new methods and compositions for improved polynucleotide synthesis over a wide variety of experimental conditions.</p>
    <heading>SUMMARY OF THE INVENTION</heading> <p>The subject invention provides novel compositions containing a mixture of (a) an enzyme that possesses substantial 3'-5' exonuclease activity and (b) a DNA polymerase with less 3'-5' exonuclease activity than the enzyme possessing substantial 3'-5' exonuclease activity. Preferably, the enzyme with substantial 3'-5' exonuclease activity is a DNA polymerase. Preferably, the DNA polymerase with less 3'-5' exonuclease activity than the enzyme possessing substantial 3'-5' exonuclease activity is a DNA polymerase substantially lacking 3'-5' exonuclease activity. When a step in a technique of interest employing polynucleotide synthesis involves the step of incubation at an elevated temperature, e.g., PCR, both the DNA polymerase and the enzyme with substantial 3'-5' exonuclease activity are thermostable enzymes. A preferred embodiment of the invention is a composition comprising the Taq DNA polymerase (from Thermus aquaticus) and the Pfu DNA polymerase (from Pyrococcus furiosus).</p>
    <p>Another aspect of the invention is to provide methods for synthesizing polynucleotides, typically DNA, using compositions comprising an enzyme that possesses substantial 3'-5' exonuclease activity and DNA polymerase with less 3'-5' exonuclease activity than the enzyme with substantial 3'-5' exonuclease activity. Preferably, the DNA polymerase used in the provided methods is a DNA polymerase that substantially lacks 3'-5' exonuclease activity. The methods of synthesizing DNA (or other polynucleotides) provided comprise the step of mixing a composition containing (a) an enzyme possessing substantial 3'-5' exonuclease activity and (b) a DNA polymerase with less 3'-5' exonuclease activity than the enzyme with substantial 3'-5' exonuclease activity. Other reagents required for polynucleotide synthesis include nucleotide triphosphates (dNTPs), polynucleotide primers, a synthesis template, and the like.</p>
    <p>Another aspect of the invention is to use the subject method of polynucleotide synthesis to carry out the synthesis step in a polymerase chain reaction experiment.</p>
    <p>Yet another aspect of the invention is to provide kits for the synthesis of polynucleotides, wherein the kits comprise an enzyme that possesses substantial 3'-5' exonuclease activity and a DNA polymerase with less 3'-5' exonuclease activity than the enzyme with substantial 3'-5' exonuclease activity, preferably a DNA polymerase substantially lacking 3'-5' exonuclease activity. Preferably, the enzyme with substantial 3'-5' exonuclease activity is a DNA polymerase. The kits may also contain polynucleotide precursors, synthesis primers, synthesis templates, buffers, and the like.</p>
    <heading>DESCRIPTION OF SPECIFIC EMBODIMENTS</heading> <p>The subject invention provides novel composition for use in synthesizing polynucleotides, particularly DNA. The subject compositions comprise an enzyme that possesses substantial 3'-5' exonuclease activity and a DNA polymerase with less 3'-5' exonuclease activity than the enzyme with substantial 3'-5' exonuclease activity. In a preferred embodiment of the invention, the DNA polymerase in the compositions is a DNA polymerase that substantially lacks 3'-5' exonuclease activity. The enzyme that possesses substantial 3'-5' exonuclease activity is preferably a DNA polymerase. Prior to the inventors work, DNA synthesis in vitro was performed with a single purified DNA polymerase. In a variety of synthesis procedures, the subject compositions provide superior synthesis results, as compared with the synthesis results obtained with a single DNA polymerase with less 3'-5' exonuclease activity than the enzyme with 3'-5' exonuclease activity alone (including synthesis results obtained with DNA polymerases that substantially lack 3'-5' exonuclease activity).</p>
    <p>Although compositions comprising a DNA polymerase with less 3'-5' exonuclease activity than the enzyme possessing substantial 3'-5' exonuclease activity may produce superior results in a variety of synthesis experiments, the composition is especially useful in DNA synthesis when there exists one or more mismatched nucleotide(s), particularly mismatches at the 3' end of one or more synthesis primer(s). In such situations, the results achieved, i.e., the amount of synthesis product produced, are significantly greater than the amount of synthesis product obtained using either a DNA polymerase with less 3'-5' exonuclease activity than the enzyme possessing substantial 3'-5' exonuclease activity or with a DNA polymerase possessing substantial 3'-5' exonuclease activity alone. Other advantages of the subject compositions and methods include increased synthesis product yield, increased transcription product length, and the synthesis of polynucleotides that can not be synthesized by a given DNA polymerase alone.</p>
    <p>The enzyme possessing substantial 3'-5' exonuclease activity for use in the subject compositions and methods may be any enzyme possessing substantial 3'-5' single- stranded DNA exonuclease activity. Enzymes possessing substantial 3'-5' exonuclease activity for use in the present compositions and methods may be isolated from natural sources or produced through recombinant DNA techniques. Enzymes that possess substantial 3'-5' exonuclease activity and their properties are described in detail in, among other places, DNA Replication 2nd edition, Kornberg and Baker, supra and Enzymes, supra. Examples of enzymes that possess substantial 3'-5' exonuclease activity include E coli exonuclease I, E. coli exonuclease III, E. coli recBCD nuclease, mung bean nuclease, and the like. Preferred enzymes with substantial 3'-5' exonuclease activity for use in the subject compositions and methods are DNA polymerases that possess substantial 3'-5' exonuclease activity.</p>
    <p>DNA polymerases that possess substantial 3'-5' exonuclease activity include the Pfu DNA polymerase, E. coli DNA polymerase I, Klenow fragment, T-4 polymerase, T-7 polymerase, E. coli DNA pol III, Ultima DNA Polymerase (Cetus), Vent DNA and Deep Vent DNA polymerases (New England Biolabs). When using the subject compositions in reaction mixtures that are exposed to elevated temperatures, e.g., during the PCR technique, use of thermostable DNA polymerases is preferred. Examples of the thermostable DNA polymerases that possess substantial 3'-5' exonuclease activity include Vent DNA polymerase, Ultima DNA polymerase, Deep Vent DNA polymerase, and Pfu DNA polymerases. A particularly preferred DNA polymerase possessing 3'-5' exonuclease activity for use in subject composition is the Pfu DNA polymerase. The Pfu DNA polymerase is commercially available from Stratagene (La Jolla, Calif.). A detailed description of the Pfu DNA polymerase can be found, among other places in U.S. patent application Ser. No. 07/803,627 filed Dec. 2, 1991.</p>
    <p>DNA polymerases and their properties are described in detail in, among other places, DNA Replication 2nd edition, Kornberg and Baker, W. H. Freeman, New York, N.Y. (1991). DNA polymerases with less 3'-5' exonuclease activity for use in the subject compositions and methods may be isolated from natural sources or produced through recombinant DNA techniques. DNA polymerases with less 3'-5' exonuclease activity than the 3'-5' exonuclease activity of the enzyme with substantial 3'-5' exonuclease activity, i.e., 3'-5' single-stranded exonuclease activity, include Taq DNA polymerases and Sequenase™(modified bacteriophage T7 DNA polymerase, available from U.S. Biochemical, Columbus, Ohio), and the like. Additionally, the person of average skill in the art having the benefit of this disclosure will recognize that exonuclease deficient polymerases such as Exo<sup>-</sup> Pfu DNA polymerase, Vent® (exo<sup>-</sup>) DNA polymerase, Deep Vent® (exo-) DNA polymerase, and the like may be suitably used in the subject compositions. Taq DNA polymerase, Sequenase™, Exo<sup>-</sup> Pfu DNA polymerase, Vent (exo<sup>-</sup>) DNA polymerase, and Deep Vent (exo<sup>-</sup>) DNA polymerase are all examples of DNA polymerases that substantially lack 3'-5' exonuclease activity.</p>
    <p>When using the subject compositions in reaction mixtures that are exposed to elevated temperatures, e.g., during the PCR technique, use of thermostable DNA polymerases is preferred. The subject composition may also be used with DNA polymerases that have not yet been isolated, provided that the DNA polymerases have less 3'-5' single-stranded DNA exonuclease activity than the enzyme with substantial 3'-5' exonuclease activity in the subject composition. Assays for both DNA polymerase activity and 3'-5' exonuclease activity can be found in DNA Replication 2nd Ed., Kornberg and Baker, supra, Enzymes, Dixon and Webb, Academic Press, San Diego, Calif. (1979), as well as other publications available to the person of ordinary skill in the art. A preferred DNA polymerase for use in the subject compositions and methods of the invention is the Taq DNA polymerase.</p>
    <p>The term "substantially lacking 3'-5' exonuclease activity" when used in reference to a DNA polymerase, refers to those DNA polymerases that have less 3'-5' exonuclease activity than the enzyme included in the subject composition that has substantial 3'-5' exonuclease activity.</p>
    <p>The term "thermostable" when used with respect to an enzyme, is readily understood by a person of ordinary skill in the art. Typically, a "thermostable" enzyme retains at least 50 percent of its specific activity after exposure to a temperature of 80° C. for a period of 20 minutes.</p>
    <p>The ratio of the DNA polymerase with less 3'-5' exonuclease activity than the enzyme possessing substantial 3'-5' exonuclease activity to the enzyme possessing substantial 3'-5' exonuclease activity in the subject composition may be varied with respect to one another. The ratio of the DNA polymerase activity to 3'-5' exonuclease activity present in the subject composition employed in a given synthesis procedure may be readily optimized by performing a series of simple experiments in which the ratio of the DNA polymerase with less 3'-5' exonuclease activity than the enzyme with substantial 3'-5' exonuclease activity to the enzyme possessing substantial 3'-5' exonuclease activity are systematically varied with respect to one another and the synthesis results compared.</p>
    <p>The subject compositions may be used in various methods of synthesizing polynucleotides in essentially the same manner as the DNA polymerase present in the subject composition. Typically, synthesis of a polynucleotide requires a synthesis primer, a synthesis template, polynucleotide precursors for incorporation into the newly synthesized polynucleotide, (e.g. dATP, dCTP, dGTP, dTTP), and the like. Detailed methods for carrying out polynucleotide synthesis are well known to the person of ordinary skill in the art and can be found, for example, in Molecular Cloning second edition, Sambrook et al., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989). The process of PCR employs a polynucleotide synthesis step in each cycle; this polynucleotide synthesis step may be achieved using the subject compositions.</p>
    <p>The invention herein also contemplates a kit format which comprises a package unit having one or more containers of the subject composition and in some embodiments including containers of various reagents used for polynucleotide synthesis, including synthesis in PCR. The kit may also contain one or more of the following items: polymerization enzymes, polynucleotide precursors, primers, buffers, instructions, and controls. Kits may include containers of reagents mixed together in suitable proportions for performing the methods in accordance with the invention. Reagent containers preferably contain reagents in unit quantities that obviate measuring steps when performing the subject methods.</p>
    <p>The following examples are offered for the purpose of illustrating, not limiting, the subject invention.</p>
    <heading>BACKGROUND OF EXAMPLES</heading> <heading>CHARACTERISTICS OF TAQ AND PFU DNA POLYMERASES</heading> <p>Thermus aquaticus DNA Polymerase</p>
    <p>Thermus aquaticus (Taq) DNA polymerase is a 94-kDa protein which does not have an inherent 3' to 5' exonuclease activity (Tindall, K. R., and T. A. Kunkel. 1988. Fidelity of DNA synthesis by the Thermus aquaticus DNA polymerase. Biochemistry 27:6008-6013). 3' to 5' exonuclease activity enables a polymerase to proofread and is therefore associated with fidelity of an enzyme. The estimated error rate of Taq varies from 2×10<sup>-4</sup> mutations per nucleotide per cycle during PCR (Saiki, R. K., D. H. Gelfand, S. Stoffel, S. J. Scharf, R. Higuchi, G. T. Horn, K. B. Mullis, and H. A. Erlich. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. 1988. Science 239:487-491) to 2×10<sup>-5</sup> for nucleotide substitution errors in a single round of DNA synthesis of the lacZα gene (Eckert, K. A. and T. A. Kunkel. High fidelity DNA synthesis by the Thermus aquaticus DNA polymerase. 1990. Nucleic Acids Res. 18:3739-3744). The error rate of Taq DNA polymerase is important in polymerization because it reflects the ability of the polymerase to extend from a mismatched primer:template. Taq DNA polymerase has been shown to extend significantly less efficiently from a mismatched primer: template than from a correctly based paired primer:template (Innis, M. A., K. B. Myambo, D. H. Gelfand and M. A. D. Brow. DNA sequencing with Thermus aquaticus DNA polymerase and direct sequencing of polymerase chain reaction-amplification of DNA. 1988. Proc. Natl. Acad Sci. USA. 85:9436-9440 and Kwok, S., D. E. Kellogg, D. Spasic, L. Goda, C. Levenson, and J. J. Sninsky. Effects of primer-template mismatches on the polymerase chain reaction: Human immunodeficiency virus type 1 model studies. 1990. Nucleic Acids Res. 18:999-1005).</p>
    <p>Taq DNA polymerase is highly processive at an extension rate of &gt;60 nucleotides per second at 70° C. on M13 phage DNA when using a GC-rich 30 mer as a primer (Innis, et al. 1988). The Taq genome is 66.8% GC (Munster, M. J., A. P. Munster, J. R. Woodrow, and R. J. Sharp. Isolation and preliminary taxonomic studies of Thermus strains isolated from Yellowstone National Park, USA. 1986. J. of Gen. Microbiol. 132:1677-1683).</p>
    <p>Pyrococcus furiosus DNA polymerase</p>
    <p>Pyrococcus furiosus (Pfu) DNA polymerase is a 91-kDa protein which has an inherent 3' to 5' exonuclease activity. This proofreading activity allows Pfu to extend from mismatched primer:templates by first removing the mismatched base(s) followed by polymerization and results in an error rate of 1.6×10<sup>-6</sup> mutations per nucleotide per cycle in PCR reactions. The error rate of Pfu DNA polymerase is thus tenfold lower than that of Taq DNA polymerase and results in higher fidelity (Lundberg, K. S., D. D. Shoemaker, M. W. W. Adams, J. M. Short, J. A. Sorge, and E. J. Mathur. High-fidelity amplification using a thermostable DNA polymerase isolated from Pyrococcus furiosus. 1991. Gene 108:1-6). The processivity of Pfu DNA polymerase is 10-15 nucleotides per second and its genome is 38% GC.</p>
    <heading>TEMPLATES</heading> <p>cDNA templates</p>
    <p>cDNAs from 2 sources, hybridoma and PBLs (peripheral blood lymphocytes), were chosen as templates in these experiments. Hybridoma cDNA from human anti-tetanus toxoid 9F12 (ATCC, HM-8177) and mouse anti-human fibronectin CG7C7 (ATCC, HB-126) express only one immunoglobulin heavy and light chain and therefore would contain a homogeneous population of heavy and light chain cDNAs. The 9F12 cDNA had amplified efficiently in previous experiments when using primers AB-61 or MK-205 with AB-76 (Fd) or MK-39 (VH), AB-25 and AB-94 (light chain[LC]), and MK-94 and AB-76 (CH1). Based on nucleotide sequence, 9F12 is a human IgG1 from the VHIII family with a kappa light chain. The SA-13 cDNA had amplified efficiently in previous experiments when using primers AB-19 with AB-41 (Fd) and AB-25 and AB-26 (LC). PBL cDNA expresses immunoglobulin heavy and light chains from all of the human heavy and light chain families (Kabat, T. T. Wu, H. Bilofsky, M. Reid-Milner, and H. Perry, eds. Sequences of Proteins of Immunological Interest, 1987, U.S. Public Health Service, Washington, D.C.) and therefore would contain a heterogenous population of heavy and light chain cDNAs. This cDNA had not amplified efficiently with primer AB-61 or MK-205 with AB-76 (Fd) or MK-39 (VH) but had amplified efficiency with AB-25 and AB-94 (LC) and MK-94 and AB-76 (CH1) (Table 13).</p>
    <p>DNA templates</p>
    <p>Nine different DNA templates were also used in these experiments. The genomic DNAs were isolated from human, Epstein Barr virus, Escherichia coli, and transgenic and nontransgenic mouse. Plasmid DNAs were pBluescript II and pBluescript containing the light chain and Fd of an anti-tetanus toxoid immunoglobulin (Mullinax R. L., E. A. Gross, J. R. Amberg, B. N. Hay, H. H. Hogrefe, M. M. Kubitz, A. Greener, M. Alting-Mees, D. Ardourel, J. M. Short, J. A. Sorge, and B. Shopes. 1990. Identification of human antibody fragment clones specific for tetanus toxoid in a bacteriophage lambda immunoexpression library. Proc. Natl. Acad. Sci. USA 87:8095-8099).</p>
    <heading>PRIMER DESIGN</heading> <p>The ability of an oligonucleotide to act as a primer in DNA synthesis is dependent on several factors: the kinetics of association and dissociation of the primer:template duplexes under the annealing and extension conditions, the effects of mismatched bases and their location on duplex stability, and the efficiency with which the polymerase can recognize and extend from a mismatched duplex. In general, single base pair mismatches at or near the terminal 3' base of a primer are known to affect the ability of the polymerase to bind and extend from the primer:template and therefore should have a significant effect on the efficiency of the priming reaction.</p>
    <p>In particular, Taq DNA polymerase requires that 3 to 5 bases at the 3' end of the primer base pair exactly in order for polymerization to occur. The effect of other mismatches on the efficiency of polymerization is dependent on the number of mismatches and where they occur in the primer. This presents a problem when the exact template sequence is not known such as when the nucleotide sequence of the template is derived from amino acid sequence due to the redundancy of the amino acid code and when designing primers for templates of families of genes which are heterogeneous.</p>
    <p>Four oligonucleotide primers designed to specifically prime the first constant region of human heavy chain immunoglobulin genes (VH) were designed based on the available nucleotide and amino acid sequences with the problems above in mind (Mullinax, et al., 1990). Because experimental results indicated poor priming and/or amplification efficiency with PBL templates with Taq DNA polymerase, we wanted to investigate how this efficiency could be improved.</p>
    <p>One of the human heavy chain first constant region primers, AB-61 (Table 15) was chosen for examination. AB-61 has a dGTP as the 3' base and would require a dCTP in the corresponding position in the template in order for efficient priming to occur when Taq DNA polymerase was used for primer extension due to its lack of 3' to 5' exonuclease activity (Kwok, et al. 1990, supra). However, Pfu DNA polymerase does have 3' to 5' exonuclease activity and would remove any mismatched base(s) from the 3' end of the primer and would therefore be able to extend (Lundberg, et al. 1991, supra). Therefore it was of interest to investigate the effect of using Pfu DNA polymerase alone and in combination with Taq DNA polymerase in primer extension reactions using cDNA from hybridoma cell lines (9F12 and CG7C7) and from human PBLs as the template under various experimental conditions.</p>
    <p>Kwok, et al. (1990) demonstrated that primer extension efficiency when using Taq DNA polymerase is independent of the dNTP in the template when a dTTP is the 3' base in the primer. Therefore the effect of the addition of one or more dTTPs in various positions at the 3' end of the primer AB-61 (Table 13) was also investigated.</p>
    <heading>BUFFER COMPARISONS</heading> <p>Buffer conditions have been shown to effect the processivity, activity and fidelity of polymerases. In particular, the processivity and/or activity of Taq DNA polymerase are known to be affected by KCI, MgCl<sub>2</sub>, (NH<sub>4</sub>)<sub>2</sub> SO<sub>4</sub>, and NaCl<sub>1</sub> concentrations. The fidelity of Taq DNA polymerase is also affected by the concentration of MgCl<sub>2</sub> relative to the total concentration of dNTPs (Eckert, et al. 1990, supra) and dNTP and MnC12 concentrations (Leung, D. W., E. Chen, and D. V. Goeddel. 1989). A method for random mutagenesis of a defined DNA segment using a modified polymerase chain reaction. Technique. 1:11-15).</p>
    <p>Table 17 lists the buffer components and their concentrations for the 10×Taq DNA polymerase and Pfu V25, #1, and #3 buffers used in these experiments.</p>
    <heading>DIFFERENT RATIOS OF TAQ AND PFU DNA POLYMERASES</heading> <p>Taq DNA polymerase is unable to correct nucleotide misincorporations made during polymerization due to its lack of 3' to 5' exonuclease activity. In general, this would result in the inability of Taq to extend from a newly polymerized strand annealed to a template when an incorrect nucleotide has been inserted. Pfu DNA polymerase has an inherent 3' to 5' exonuclease activity and would be able to remove the incorrectly inserted nucleotide and then extend from the correctly base paired primer:template. The ratio of the two polymerases may be critical for optimal efficiency of this process. We therefore compared several ratios of Taq:Pfu DNA polymerases to determine the effect on DNA synthesis from 3' matched and mis-matched primers.</p>
    <p>In addition, Pfu DNA polymerase has been shown to degrade unannealed primers by its 3' to 5' exonuclease activity. These degraded primers would not be available in subsequent rounds of DNA amplification and would therefore effect the efficiency of the PCR reaction. It may therefore be desirable to have a low concentration of Pfu DNA polymerase relative to Taq DNA polymerase to decrease this effect.</p>
    <heading>EXAMPLE 1</heading> <heading>PRIMER EXTENSION WITH TAQ OR PFU DNA POLYMERASE IN SEPARATE REACTIONS</heading> <p>These experiments demonstrate the relative ability of Taq or Pfu DNA polymerase to PCR amplify hybridoma and PBL templates under various conditions. Taq DNA polymerase resulted in either the presence of a PCR product or an increase in the amount of PCR product when compared to Pfu DNA polymerase when amplifying hybridoma and PBL templates. In addition, the dNTP and not the MgCl<sub>2</sub> concentration affected the amount of LC product generated.</p>
    <p>Taq and Pfu DNA polymerases with CG7C7 hybridoma template</p>
    <p>Taq and Pfu DNA polymerases were compared for their ability to amplify the LC, CH1, and Fd regions of a mouse anti-human fibronectin antibody (CG7C7, ATCC HB-126). Total RNA was isolated from CG7C7 hybridoma cells using an RNA isolation kit (Stratagene). Five μg of total RNA was converted to cDNA in a first strand synthesis reaction using an oligo-dT primer for the light chain and AB-41 for the heavy chain (Table 15). mRNA was annealed to the first strand primer at 65° C. for 5 minutes followed by cooling at room temperature for 30 minutes. First strand reactions were performed in 1× first strand buffer [1× first strand buffer is 75 mM KCl; 50 mM tris-C1, pH 8.3; 10 mM dithiothreitol; 3 mM MgCl<sub>2</sub> ; 1 Unit RNase Block II (Stratagene)], 375 μM each dNTP and 20 Units Moloney-Murine Leukemia Virus Reverse Transcriptase (M-MLVRT) (Stratagene)] and incubated at 37° C. for 1 hour and then 42° C. for 30 minutes.</p>
    <p>PCR primers used to amplify the LC were AB-25 and AB-26, CH1 were MK-501 and AB-41, Fd were AB-41 and AB-19, and the polylinker region of pBluescript were T3 and T7 (Table 14). PCR reactions with Taq DNA polymerase were at a primer concentration of 0.2 μM of each 5' and 3' primer in 1x Taq buffer (Table 17) with 200 μM each dNTP and 2.5 units Taq DNA polymerase (Stratagene; La Jolla, Calif.) using 1/10 of cDNA prepared in the first strand reaction as the template. Samples were denatured at 99° C. for 5 minutes and annealed at 54° C. for 5 minutes followed by PCR amplification at 72° C. for 3 minutes, 93° C. for 1.5 minutes and 54° C. for 2 minutes for cycles.</p>
    <p>PCR reactions with Pfu DNA polymerase were performed under the same conditions but with 1× V25 buffer instead of Taq buffer.</p>
    <p>Twenty μl of the 100 μl reaction was separated on an agarose gel by electrophoresis and visualized by staining with ethidium bromide. Results are indicated by the relative amount of appropriately sized PCR product and all given in Table 1.</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">              TABLE 1______________________________________Taq and Pfu DNA polymerases with CG7C7 template                             V25                   Taq buffer                             bufferProduct    Primers      Taq       Pfu______________________________________Fd         AB-19/AB-41  2+        +/-CH1        MK-501/AB-41 2+        +LC         AB-25/AB-26  +         -polylinker T3/T7        +         -______________________________________ *The relative amounts of PCR product are indicated as a range of no product (-) to the most product (5+).</pre>
    
    <p>Results from this experiment indicate that only Taq DNA polymerase produced an appropriately sized PCR product with all of the primer pairs used. Pfu DNA polymerase produced either less or no product when compared to Taq DNA polymerase with all of the primer pairs.</p>
    <p>The CH1 primers were designed for amplification of constant regions of the antibody heavy chain and would be expected to base pair match perfectly with their template. The T3 and T7 primers also base pair match perfectly with the pBluescript template.</p>
    <p>Taq and Pfu DNA polymerases with PBL template</p>
    <p>Taq DNA polymerase was used to amplify the LC (both kappa and lambda), CH1, CH2/CH3, and Fd regions of human PBL immunoglobulins. The MgCl<sub>2</sub> and dNTP concentrations were varied to try to increase the amount of PCR product generated. Total RNA was isolated from human PBLs using an RNA isolation kit (Stratagene). Five ug of total RNA was converted to cDNA in a first strand synthesis reaction using an oligo-dT primer for the LC, and MK-25 for the heavy chain. mRNA was annealed to the first strand primer at 65° C. for 5 minutes followed by cooling at room temperature for 30 minutes. First strand reactions were performed in 1× first strand buffer [1× first strand buffer is 75 mM KCl; 50 mM tris-C1, pH 8.3; 10 mM dithiothreitol; 3 mM MgCl<sub>2;</sub> 1 Unit RNase Block II (Stratagene)], 375 μM each dNTP and 20 Units Moloney-Murine Leukemia Virus Reverse Transcriptase (M-MLVRT) (Stratagene)] and incubated at 42° C. for 1 hour.</p>
    <p>PCR primers used to amplify the kappa LC were AB-25 and AB-26, lambda LC were AB-92 and AB-28, CH2/CH3 were MK-25 and MK-26, Fd were AB-52 with AB-61, AB-62, AB-63, or AB-64 (Table 18). PCR reactions were at a primer concentration of 0.2 μM of each 5' and 3' primer in 1× Taq buffer (Table 17) with 2.5 units Taq DNA polymerase using 1/10 of cDNA prepared in the first strand reaction as the template. The kappa LC reaction was 2.0 mM MgCl<sub>2</sub> with 237.5 μM dNTPs, the lambda LC reaction was 1.8 mM MgCI<sub>2</sub> at 137.5 μM or 237.5 μM dNTPs, the Fd reactions were 1.9 mM MgCl<sub>2</sub> with 187.5 μM dNTPs, and the CH2/CH3 reactions were at 1.5 mM MgCl<sub>2</sub> with 137.5 μM dNTPs. Samples were denatured at 94° C. for 5 minutes and annealed at 54° C. for 5 minutes followed by PCR amplification at 72° C. for 2.5 minutes, 93° C. for 1 minute and 54° C. for 1.5 minutes for 40 cycles. Samples were analyzed as described above. Results are indicated by the relative amount of appropriately sized PCR product and are given in Table 2.</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">              TABLE 2______________________________________Taq and Pfu DNA polymerases with PBL templatePBL template      1.9      mM      MgCl<sub>2</sub>            1.8 mM MgCl<sub>2</sub>                        2.0 mM MgCl<sub>2</sub>            187.5   137.5 237.5 137.5 237.5    pro-    μM   μM μM μM μMprimers  duct    dNTP    dNTP  dNTP  dNTP  dNTP______________________________________AB-61/AB-52    Fd      -AB-62/AB-52    Fd      -AB-63/AB-52    Fd      -AB-64/AB-52    Fd      -MK-25/   CH2/3   -       -     -     -     -MK-26AB-25/AB-26    kappa                             4+    LCAB-92/AB-28    lambda          +     4+    +     4+    LC______________________________________</pre>
    
    <p>Only the kappa and lambda LC reactions produced a specific PCR product. The 1.8 and 2.0 mM MgCl<sub>2</sub> with 137.5 μM dNTP lambda LC reactions produced only a very small amount of PCR product while the 1.8 and 2.0 mM MgCI<sub>2</sub> with 237.5 μM dNTPs produced a large amount of PCR product. This indicates that the amount of PCR product in this experiment is related to the dNTP and not the MgCI<sub>2</sub> concentration. No PCR product was generated with the Fd or CH2/CH3 primers under the conditions used.</p>
    <heading>EXAMPLE 2</heading> <heading>PRIMER EXTENSION REACTIONS WITH 3' MISMATCHED PRIMERS</heading> <p>These experiments investigated the ability of Taq and Pfu DNA polymerases both together and in separate reactions to extend from primers which contain one or two 3' mismatches. The first experiment demonstrates that Taq DNA polymerase can only extend from a primer which matches at the 3' end under the conditions used (2.1 and 6.1 mM MgCI<sub>2</sub>). The next experiment demonstrates that Taq and Pfu DNA polymerases used in the same reaction will extend from all the primers with 3' mismatches that were used from both hybridoma and PBL templates while neither polymerase alone was able to extend from all primers. The combination of both polymerases also resulted in more product in some of the samples.</p>
    <p>This series of experiments suggest that Taq in Taq buffer will extend from a primer that is perfectly matched at the 3' end, in V25 buffer will extend from a primer that has one T which creates a mismatch at the 3' end of a primer, and in V25 buffer will not extend from a primer that has two Ts which create two mismatches at the 3' end of a primer. Taq and Pfu DNA polymerases in V25 buffer will extend from a primer that has two Ts which create a mismatch at the 3' end of a primer.</p>
    <p>It was also speculated that Taq and Pfu DNA polymerases may complement each other in the reaction by polymerizing through A:T or G:C rich regions of a template where one enzyme could not polymerize well through both types of regions. The Pfu genome is 38% GC while the Taq genome is 66.8% GC.</p>
    <p>Taq DNA polymerase with 9F12 template</p>
    <p>The ability of Taq DNA polymerase to extend from primers with one or more mismatches at the 3' end was investigated. Nucleotide sequences of the 5' primers based on the AB-61 primer and used to amplify 9F12 cDNA are given in Table 12. The 3' primer in reactions which amplified the Fd portion of the human heavy chain was AB-76. The 3' primer in reactions which amplified the VH portion of the human heavy chain was MK-39. The light chain 5' VL primer was AB-25 and the 3' CL primer was AB-94.</p>
    <p>9F12 cDNA template was generated by isolating total RNA from the hybridoma cells using an RNA isolation kit (Stratagene). mRNA is converted to cDNA in a first strand synthesis reaction using an oligo-dT primer for the light chain and AB-76 for the heavy chain. The first strand reactions was performed as described above except 200 units of Superscript (BRL; Gaithersburg, MD)] was substituted for M-MLVRT and the reactions were incubated at 42° C. for 1 hour.</p>
    <p>PCR reactions were at a primer concentration of 0.2 μM of each 5' and 3' primer in 1× Taq buffer (Table 17) with either 2.1 or 6.1 mM MgCl<sup>2</sup>, 175 μM each dNTP and 2.5 units Taq DNA polymerase using 1/10 of the cDNA prepared in the first strand reaction as the template. Samples were denatured at 95° C. for 5 minutes and annealed at 54° C. for 5 minutes followed by PCR amplification at 72° C. for 3 minutes, 93° C. for 1.5 minutes and 54° C. for 2.5 minutes for 40 cycles. Samples were analyzed as described above and the results are given in Table 3.</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">              TABLE 3______________________________________Taq DNA polymerase with 9F12 template         Taq in Taq bufferprimers   product   2.1 mM MgCl<sub>2</sub>                           6.1 mM MgCl<sub>2</sub>______________________________________AB-61/AB-76     Fd        2+          -AB-714/AB-76     Fd        -           -AB-715/AB-76     Fd        -           -AB-716/AB-76     Fd        -           -AB-717/AB-76     Fd        -           -AB-61/MK-39     VH        2+          +______________________________________</pre>
    
    <p>PCR products of the appropriate size were generated only when AB-61 was used as the 5' primer. None of the 3' mismatched primers generated a PCR product of the appropriate size although many unappropriately sized products were made. Fd and VH products were generated in the reaction containing 2.1 mM MgCl<sub>2</sub> while only the VH was produced in the reaction containing 6.1 mM MgCl<sub>2</sub>.</p>
    <p>These results suggested that Taq DNA polymerase was not able to extend from 3' mismatched primers under the conditions used and that increasing the MgCI<sub>2</sub> concentration did not result in either an increase in PCR product, the ability to extend from 3' mismatched primers, or generation of PCR products not made with 2.1 mM MgCl<sub>2</sub>.</p>
    <p>Taq and Pfu DNA polymerases with 9F12 and PBL templates</p>
    <p>The next experiment investigated the effect of using Pfu and Taq DNA polymerases in the same PCR reaction to extend from primers with 3' matches and mismatches. The same primers were used (MK-205 which has the same 21 bp on the 3' end as AB-61 was substituted for AB-61) as described above to amplify Fd, VH, CH1, and LC from PBL and 9F12 cDNAs. PCR reactions were performed in 1× V25 buffer (Table 17) with 200 μM each dNTP and 2.5 units of both Taq and Pfu DNA polymerases or with Pfu DNA polymerase alone using cDNA generated as described above from 9F12 &amp; PBL RNA as the template. Samples were denatured at 94° C. for 5 minutes and annealed at 47° C. for 5 minutes followed by PCR amplification at 71° C. for 3 minutes, 92° C. for 1 minute and 47° C. for 2.5 minutes for 5 cycles and 71° C. for 3 minutes, 92° C. for 1 minute and 51 ° C. for 2.5 minutes for 35 cycles. The lower annealing temperatures were used to try to improve primer:template annealing when mismatches occurred. Samples were analyzed as described above and the results are given in Tables 4 and 5.</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">              TABLE 4______________________________________Taq and Pfu DNA polymerases with 9F12 and PBL templatesV25 buffer      9F12 template                 PBL template      Pfu/Taq        Pfuprimers      Fd     VH        Fd    VH______________________________________AB-61/AB-76  5+     5+        +     +/-AB-714/AB76  5+     5+        2+    +/-AB-715/AB76  2+     5+        +/-   +/-AB-716/AB76  5+     5+        2+    +/-AB-717/AB76  5+     5+        +     +/-______________________________________</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">              TABLE 5______________________________________          9F12      PBL          templates templates          Pfu/Taq       Pfuprimers    product   Fd      VH    Fd    VH______________________________________MK-94/AB-76      CH1       5+            +/-   +/-AB-25/AB-94      LC        +/-           +/-   +/-______________________________________</pre>
    
    <p>An unexpected result in this experiment was that more amplification product was generated when Taq and Pfu DNA polymerases were used in the same PCR reaction in V25 buffer with both 9F12 and PBL cDNA as the template. Numerous previous experiments using identical first strand synthesis and PCR conditions with Taq DNA polymerase had resulted in only a very small amount of Fd product generated from the same PBL mRNA. A very small amount of VH and CH1 products were generated using Pfu DNA polymerase alone in V25 buffer with PBL cDNA as a template.</p>
    <p>Significant amounts of both Fd and VH PCR products were generated with 9F12 cDNA as a template with all of the 5' primers, including the 3' mismatched primers (AB-714 to AB-717), when both Taq and Pfu DNA polymerases were used. This contrasted with the previous experiment when Taq DNA polymerase was not able to extend from the 3' mismatched primers (AB-714 through AB-717) under the conditions used. These results suggested that Pfu DNA polymerase can remove 1-2 mismatched bases from the 3' end of the primer. This would enable either Pfu or Taq DNA polymerase to extend from the perfectly base paired primer:template. Taq and Pfu DNA polymerases with 9F12 and PBL templates</p>
    <p>The above experiment was repeated to verify the results. The same primers were used to amplify Fd, CH1, and LC using PBL and 9F12 cDNAs as templates. PCR reactions were performed in V25 buffer (Table 17) with 200 μM each dNTP and 2.5 units of both Taq and Pfu DNA polymerases either together in the same reaction and or in separate reactions. PCR conditions were the same as described above and the results are given in Table 5.</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">              TABLE 6______________________________________Taq and Pfu DNA Polymerases with 9F12 and PBL Templates        V25 buffer        9F12 template                   PBL template                          Pfu/           Pfu/primers   product  Taq    Pfu  Taq  Taq  Pfu  Taq______________________________________AB-61/AB-76     Fd       -      -    +    -    +    -AB-714/AB-76     Fd       3+     -    4+   +    -    3+AB-715/AB-76     Fd       -      -    2+   -    -    +AB-716/AB-76     Fd       4+     -    4+   3+   +    +AB-717/AB-76     Fd       2+     -    4+   +    -    3+MK94/AB-76     CH1      4+     4+   4+   3+   -    -AB-25/AB-94     LC       2+     -    -    +    -    -______________________________________</pre>
    
    <p>PCR products generated with Pfu were Fd with MK-205 from PBL template and CH1 from 9F 12 template. PCR products generated with Taq were Fd with AB-714, AB-716, AB-717, CH1, and LC with PBL template and Fd with AB-714, AB-716, AB-717, CH1 and LC with 9F12 template. PCR products generated with Pfu and Taq were Fd with MK-205, AB-714, AB-717 and a very small amount with AB-715 and AB-716 from PBL template. PCR products generated with Pfu and Taq were Fd with AB-714, AB-715, AB-716, AB-717 and CH1 from 9F12 template.</p>
    <p>The amount of PCR product varied, however, in general more product was generated with the 9F 12 template than with the PBL template. This may be due to the heterogeneity of the PBL template when compared to the homogeneity of the 9F12 hybridoma template. When a homogeneous template is amplified and the strand is not completed, it may anneal to its template in a subsequent round of amplification and be extended to full length. When a heterogeneous template is amplified and the strand is not complete, the chances of it annealing to its original template in a subsequent round of amplification will be related to the heterogeneity of the templates present but will be less than that of a homogeneous template. This may help explain why homogeneous templates produce more PCR product than heterogenous templates.</p>
    <p>In this experiment Taq DNA polymerase was able to extend from the 3' mismatched primers which contain only a single mismatched base (AB-714, AB-716, and AB-717) but not one that has two mismatched bases (AB-715) with both the PBL and 9F 12 cDNA templates. In a previous experiment, Taq DNA polymerase was not able to do this, however, these results are consistent with the results of Kwok, et al. (1990, supra). Both AB-715 and AB-717 contain 2 dTTPs at the 3' end of the primer but in different positions. AB-715 replaces the last two dGTPs on the 3' end and AB-717 replaces the last dGTP and adds a dTTP to the 3' end. Because the corresponding base in the template is not known, the 3' dTTP in AB-717 may not create a mismatch with the template.</p>
    <p>The V25 buffer used in this experiment had been made incorrectly and was 5 mM KCl instead of 10 mM KCl. KCl concentration has been shown to effect processivity and/or activity of Taq. This was corrected for all future experiments.</p>
    <heading>EXAMPLE 3</heading> <heading>EFFECT OF DIFFERENT RATIOS OF TAQ AND PFU DNA POLYMERASES ON EXTENSION FROM 3' MISMATCHED PRIMERS</heading> <p>This experiment investigated different ratios of Taq and Pfu DNA polymerases and template concentrations when amplifying from perfectly matched and 3' mismatched primers. Plasmid DNA which encoded an anti-tetanus toxoid immunoglobulin fragment (kappa light chain and Fd portion of the heavy chain) was used as the template (Mullinax et al. 1990, supra). Although optimal polymerase ratios and template concentrations were not identified in these experiments, additional experimentation would need to be done before concluding that they did not have an effect.</p>
    <heading>EFFECT OF PFU DNA POLYMERASE RATIO ON EXTENSION FROM 3' MISMATCHED PRIMERS</heading> <p>Five different ratios of Taq and Pfu DNA polymerases were used in PCR reactions with a combined total of 2.5 units per reaction. The ratios were 9:1, 7:3, 5:5, 3:7, and 1:9 of Taq:Pfu. The Fd primers were AB-61, AB-715, and AB-717 in V25 buffer. Anti-tetanus toxoid plasmid DNA encoding a kappa LC and Fd was used as the template. Samples were denatured at 95° C. for 7 minutes and annealed at 40° C. for 7-10 minutes followed by PCR amplification at 72° C. for 2 minutes, 95° C. for 1 minute and 50° C. for 2 minutes for 30 cycles. Samples were analyzed as described above and results are given below.</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">              TABLE 7______________________________________EFFECT OF DIFFERENT RATIOS OF TAQ ANDPFU DNA POLYMERASES ONEXTENSION FROM 3' MISMATCHED PRIMERS  pro- ratio of Taq:Pfu DNA polymerasesprimers  duct   10:0   9:1  7:3  5:5  3:7  1:9  0:10______________________________________AB-61/AB-76    Fd     4+     5+   5+   5+   5+   4+   4+AB-715/  Fd     -      5+   5+   5+   5+   2+   5+AB-76AB-717/  Fd     2+     5+   5+   5+   5+   5+   5+AB-76______________________________________</pre>
    
    <p>All PCR reactions generated a significant amount of PCR product with little variation except the reactions with AB-715 and AB-717 with Taq DNA polymerase alone and the reaction with Taq:Pfu at 1:9 with AB-715. All of the reactions which combine both Taq and Pfu DNA polymerases or contain Pfu alone produced a significant amount of product. Taq DNA polymerase alone not would be expected to extend efficiently from the 3' mismatched primers.</p>
    <p>Template concentration can affect the amplification efficiency and may explain there is little difference in the amount of PCR product in the different samples when the ratio of DNA polymerases is varied. In the next experiment, three different template concentrations were used to try to determine the effect of template concentration.</p>
    <heading>EFFECT OF TEMPLATE CONCENTRATION</heading> <p>Template concentrations were 100, 50, and 10 nanograms per reaction with either 2.5 units of Taq or Pfu DNA polymerase in the reaction in V25 buffer. The Fd primers were AB-61, AB-715, and AB-717 in V25 buffer. Samples were denatured at 95° C. for 7 minutes and annealed at 40° C. for 7-10 minutes followed by PCR amplification at 72° C. for 2 minutes, 95° C. for 1 minute and 50° C. for 2 minutes for 30 cycles. Samples were analyzed as described above and results are given in Table 8.</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">              TABLE 8______________________________________EFFECT OF TEMPLATE CONCENTRATION        template concentration        100 ng  50 ng     10 ngprimers   product  Taq    Pfu  Taq  Pfu  Taq  Pfu______________________________________AB-61/AB-76     Fd       5+     5+   5+   5+   5+   5+AB-715/AB-76     Fd       5+     5+   5+   5+   5+   5+AB-717/AB-76     Fd       5+     5+   5+   5+   5+   2+______________________________________</pre>
    
    <p>Varying the template concentration did not seem to have an effect on the amount of PCR template generated except in the 10 ng template sample with Pfu DNA polymerase alone with AB-717. The results seen previously with AB-715 where there was no amplification with Taq DNA polymerase alone was not reproduced and the experimenter indicated that an error could have been made. The experiment with AB-715 alone was repeated.</p>
    <p>This experiment repeated the experiment described above using just the AB-715 primer under the same conditions. Samples were analyzed and described above and results are given in Table 9.</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">              TABLE 9______________________________________EFFECT OF TEMPLATE CONCENTRATION        template concentration        100 ng  50 ng     10 ngprimer    product  Taq    Pfu  Taq  Pfu  Taq  Pfu______________________________________AB-715/AB-76     Fd       4+     3+   3+   2+   1+   5+______________________________________</pre>
    
    <p>The amount of PCR product generated correlated with template concentration in the reactions with Taq DNA polymerase alone and may indicate that the template concentration affects amplification efficiency from mismatched primers. No consistent effect could be correlated with Pfu DNA polymerase.</p>
    <heading>EXAMPLE 4</heading> <heading>EFFECT OF ANNEALING TEMPERATURE ON EXTENSION FROM 3' MISMATCHED PRIMERS</heading> <p>The next experiment compared Taq and Taq with Pfu in Taq and V25 buffers with mismatched primers at different annealing temperatures. This experiment demonstrates that more PCR product is generated from a perfectly matched primer at a lower annealing temperature than at a higher temperature. No product was produced with the primer with 2 mismatches under any of the conditions used.</p>
    <p>Effect of annealing temperatures of extension from 3' matched and mismatched primers Taq and Taq with Pfu in Taq and V25 buffers with mismatched primers were extended at different annealing temperatures. The Fd primers were AB-61 and AB-715. cDNA templates were prepared from PBLs and 9F12. Samples were denatured at 95° C. for 5 minutes and annealed at either 48° C. or 52° C. for 5 minutes followed by PCR amplification at 71° C. for 3 minutes, 92° C. for 1 minute and 48° C. or 52° C. for 2.5 minutes for 5 cycles and 71° C. for 3 minutes, 92° C. for 1 minute and 54° C. for 2.5 minutes for 40 cycles. The lower annealing temperatures were used determine the effect the lower temperature had on primer:template annealing when mismatches occurred. Samples were analyzed as previously described and results are given in Table 10.</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">                                  TABLE 10__________________________________________________________________________Effect of Annealing Temperatures on Extension From3' Matched and Mismatched Primers__________________________________________________________________________        annealing at 48° C. (×5 cycles)        and 52° C. (×35 cycles)        9F12 template   PBL template        Taq buffer                V25 buffer                        Taq buffer                                 V25 bufferprimers product        Taq           Pfu/Taq                Taq                   Pfu/Taq                        Taq Pfu/Taq                                 Taq                                    Pfu/Taq__________________________________________________________________________AB-61/AB-76   Fd   4+ 4+   4+ 4+   +/- +    -  +/-AB-715/AB-76   Fd   -  -    -  -    -   -    -  -__________________________________________________________________________        annealing at 54° C. (×40 cycles)        9F12 template   PBL template        Taq buffer                V25 buffer                        Taq buffer                                 V25 bufferprimers product        Taq           Pfu/Taq                Taq                   Pfu/Taq                        Taq Pfu/Taq                                 Taq                                    Pfu/Taq__________________________________________________________________________AB-61/AB-76   Fd   4+ 4+   2+ +    -   -    -  -AB-715/AB-76   Fd   -  -    -  -    -   -    -  -__________________________________________________________________________</pre>
    
    <p>PCR products generated with Pfu and Taq in Taq or V25 buffers were a very small amount of Fd using AB-61 with the PBL template at the lower and not the higher annealing temperature. PCR products generated with Taq with and without Pfu in Taq or V25 buffer using AB-61 with the 9F12 template resulted in more product at the lower rather than the higher annealing temperature. No PCR products were generated with the AB-715 primer in any samples.</p>
    <p>Results indicated that none of the polymerases or buffer combinations tested extended from the AB-715 primer. AB-61 and AB-715 differ by the deletion of two dGTPs and the addition of two dTTPs at the 3' end (Table 13). The lower annealing temperatures did produce either the presence of or an increase in the amount of PCR product generated.</p>
    <heading>EXAMPLE 5</heading> <heading>PCR REACTIONS USING PRIMERS WITHOUT 3' MISMATCHES</heading> <p>The object of the experiments with the 3' mismatched primers was to determine PCR conditions would result in a sufficient amount of high fidelity PCR product to enable cloning of the encoded immunoglobulin fragments. Therefore, the original PCR primers designed to amplify all human heavy chain genes were now used in the PCR reactions with Taq and Pfu DNA polymerases separately and in the same reaction. Results indicate that there was no significant difference in the amount of PCR product generated when either Taq or Taq and Pfu DNA polymerases were used in these experiments.</p>
    <p>Taq and Pfu DNA polymerases with 9F12 and PBL templates</p>
    <p>The first strand synthesis and PCR reactions were performed as described above under PCR REACTIONS WITH 3' MISMATCHED PRIMERS--Taq and Pfu DNA polymerases with 9F12 and PBL templates with the following change. AB-61, AB-62, AB-63, and AB-64 (Table 18) were used as the 5' VH primers. Samples were analyzed as described above and results are given in Table 11.</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">              TABLE 11______________________________________Taq and Pfu DNA Polymerases With 9F12 and PBL Templates      V25 buffer      9F12 template                 PBL template     pro-               Pfu/             Pfu/primers   duct   Taq    Pfu  Taq  Taq   Pfu   Taq______________________________________AB-61/AB-76     Fd     4+     -    -    4+    +/-   4+AB-62/AB-76     Fd     4+     -    4+   4+    +/-   4+AB-63/AB-76     Fd     4+     +    4+   +/-   -     -AB-64/AB-76     Fd     4+     -    4+   2+    -     2+MK-94/AB-76     CH1    4+     3+   4+   2+    -     3+AB-25/AB-94     LC     2+     -    3+   -     -     +______________________________________</pre>
    
    <p>PCR products generated with Pfu were a very small amount of Fd with AB-61 and AB-62 from PBL template and Fd with AB-63 and CH1 from 9F12 template. PCR products generated with Taq were Fd with all 5' primers and CH1 PBL and 9F12 templates and LC with 9F12 template. PCR products generated with Pfu and Taq were Fd with AB-61, AB-62, AB-64, CH1, and LC from PBL template. PCR products generated with Pfu and Taq were Fd with AB-62, AB-63, AB-64, CH1, and LC from 9F12 template. In general, the results with the PBL template had a lot of failure products and there was significantly more product with the 9F12 template.</p>
    <p>The inability of Pfu DNA polymerase to extend from any of the 5' primers other than AB-63 may be due to internal mismatches with 9F12 as the template and not be due to the 3' primer:template mismatches.</p>
    <heading>EXAMPLE 6</heading> <p>The effect of a combination of four different polymerases in seven different buffers was tested on three different templates. The desired effects were an increase in the amount of PCR product generated and/or an increased specificity of amplification. No effect was observed between using a combination of four polymerases and Taq DNA polymerase in the buffers tested.</p>
    <p>Seven different templates with eight different primer sets were used in this experiment. The genomic DNAs were isolated from human, Epstein Barr virus, Escherichia coli, and transgenic and normal mouse. Plasmid DNAs were pBluescript II and pBluescript containing the light chain and Fd of an anti-tetanus toxoid immunoglobulin (Mullinax et al., 1990, supra). Primer sequences and their respective DNA templates are given in Table 16. The thermostable polymerases used in this experiment were Taq, Exo<sup>+</sup> and Exo<sup>-</sup> Pfu , and ES-4 DNA polymerases (Stratagene; La Jolla, Calif.) at final concentrations of 2.5, 1.25, 1.25, and 0.125 units per reaction, respectively. PCR reactions were at a primer concentration of 0.2 μM of each 5' and 3' primer in 1× T buffer, 1× Pfu #1, or 1× Pfu #3 (Table 17) with 200 μM each dNTP. An additional reaction with Taq DNA polymerase in 1× Taq buffer was also performed. Samples were denatured at 95° C. for 5 minutes and annealed at 40° C. for 5 minutes followed by PCR amplification at 95° C. for 0.5 minutes, 40° C. for 1.5 minutes and 68° C. for 3 minutes for 25 cycles. Samples were analyzed as previously described and results are not given.</p>
    <p>Results indicated that no significant increase in the amount of PCR product generated or an increase in specificity was observed when comparing Taq DNA polymerase in Taq buffer and a combination of polymerases in the three different buffers tested. Results seemed to correlate with the buffer used and not the polymerase.</p>
    <heading>EXAMPLE 7</heading> <heading>TAQ AND PFU DNA POLYMERASES IN SPLICE OVERLAP EXTENSION REACTIONS TO GENERATE CLONING VECTORS</heading> <p>A series of lambda-based vectors were constructed to express immunoglobulin fragments on the surface of M13 phage. The example described below describes the construction of one of these vectors. Pfu and Taq DNA polymerases in combination were used to construct this vector because of the high processivity of Taq DNA polymerase and the high fidelity of Pfu DNA polymerase. The nucleotide sequence of the cpVIII expression vector matched the expected nucleotide sequence. cpVIII expression vector construction</p>
    <p>Oligonucleotide primers used to construct the IZ H-8 (-1 to 50) vector with the cpVIII protein domain were designed to encode the following: an Xho I restriction site, stop codons, nucleotide spacer sequences, an Xba I site that generates an amber codon, amino acids -1 to 50 of cpVIII, stop codons, and a Spe I restriction site.</p>
    <p>Nucleotide sequences of the primers used to amplify cpVIII from M13 Phagescript DNA (Stratagene; La Jolla, Calif.) using the 5' and 3' cpVIII primers are given in Table 19. All PCR reactions were at a primer concentration of 0.2 μM of each 5' and 3' primer in 1× V25 buffer with 200 μM each dNTP and 2.5 units each Taq and Pfu DNA polymerases. Samples were denatured at 95° C. for 5 minutes and annealed at 54° C. for 5 minutes followed by PCR amplification at 74° C. for 3 minutes, 93° C. for 1.5 minutes and 54° C. for 2.5 minutes for 30 cycles.</p>
    <p>The cpVIII encoding PCR product was restriction digested with Xho I and Spe I and ligated into the IZ H vector (Stratacyte; La Jolla, Calif.; Huse, W. D., L. Sastry, S. A. Iverson, A. S. Kang, M. Alting-Mees, D. R. Burton, S. J. Benkovic, and R. A. Lerner. Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda. 1989. Science. 246:1275-1281 ) which had previously been restriction digested with Xho I and Spe I. The ligation products were packaged with Gigapack II® Gold (Stratagene; La Jolla, Calif.) and plated with XL 1-Blue host cells. The desired construct was identified by PCR amplification of isolated phage cores with the 5' and 3' cpVIII cloning primers, converted to the plasmid format by in vivo excision with VCS M13 helper phage (Short, J., J. M Fernandez, J. A. Sorge, and W. D. Huse, Lambda ZAP: a bacteriophage lambda vector with in vitro excision proprites, 1988, Nucleic Acids Res. 16:7583-7600) and the nucleotide sequence was determined by the dideoxy method. The nucleotides was sequence as expected.</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">                                  TABLE 12__________________________________________________________________________HUMAN HEAVY CHAIN PCR PRIMERSWITH MATCHED AND 3' MISMATCHES VH PRIMERSprimerdescription      nucleotide sequence (5' to 3')__________________________________________________________________________AB-2055' VH GTCCTGTCCGAGGTGCAGCTGCTCGAGTCTG      G      (SEQ ID NO: 1)AB-615' VH AGGTGCAGCTGCTCGAGTCTGG      (SEQ ID NO: 2)AB-7145' VH AGGTGCAGCTGCTCGAGTCTGT      (SEQ ID NO: 3)AB-7155' VH AGGTGCAGCTGCTCGAGTCTTT      (SEQ ID NO: 4)AB-7165' VH AGGTGCAGCTGCTCGAGTCTGGT      (SEQ ID NO: 5)AB-7175' VH AGGTGCAGCTGCTCGAGTCTGTT      (SEQ ID NO: 6)AB-763' CH1      AGCATCACTAGTACAAGATTTGGGCTC      (SEQ ID NO: 7)AB-523' CH1      CGGGAGATCATGAGGGTGTCCTT      (SEQ ID NO: 8)MK-393' VH ATATACTAGTGAGACAGTGACCAGGGTTCC      TTGGCCCCA      (SEQ ID NO: 9)__________________________________________________________________________</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">                                  TABLE 13__________________________________________________________________________HUMAN HEAVY AND LIGHT CHAIN PCR PRIMERSprimerdescription      nucleotide sequence (5' to 3')__________________________________________________________________________AB-2055' VH GTCCTGTCCGAGGTGCAGCTGCTCGAGTCTG      G      (SEQ ID NO: 1)AB-615' VH AGGTGCAGCTGCTCGAGTCTGG      (SEQ ID NO: 2)AB-7145' VH AGGTGCAGCTGCTCGAGTCTGT      (SEQ ID NO: 3)AB-7155' VH AGGTGCAGCTGCTCGAGTCTTT      (SEQ ID NO: 4)AB-7165' VH AGGTGCAGCTGCTCGAGTCTGGT      (SEQ ID NO: 5)AB-7175' VH AGGTGCAGCTGCTCGAGTCTGTT      (SEQ ID NO: 6)AB-763' CH1      AGCATCACTAGTACAAGATTTGGGCTC      (SEQ ID NO: 7)AB-523' CH1      CGGGAGATCATGAGGGTGTCCTT      (SEQ ID NO: 8)MK-393' VH ATATACTAGTGAGACAGTGACCAGGGTTCC      TTGGCCCCA      (SEQ ID NO: 9)AB-255' VL GTGCCAGATGTGAGCTCGTGATGACCCAGT      CTCCA      (SEQ ID NO: 10)AB-943' CL TCCTTCTAGATTACTAACACTCTCCCCTGTT      GAAGCTCTTTGTGACGGGCGAACTC      (SEQ ID NO: 11)MK-945' CH1      GTCTCACTAGTCTCCACCAAGGGCCCATCGG      TC      (SEQ ID NO: 12)AB-583' CH2      CGGGAGATCATGAGGGTGTCCTT      (SEQ ID NO: 13)MK-255' CH2      CTCAGTATGGTGGTTGTGC      (SEQ ID NO: 14)MK-263' CH3      CCGGAATTCTTATCATTTACCCGGAGA      (SEQ ID NO: 15)__________________________________________________________________________ *nucleotides in bold indicate where dTTP was introduced into the AB61 primer</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">              TABLE 14______________________________________pBluescript PCR primersdescription    nucleotide sequence (5' to 3')______________________________________T3             ATTAACCCTCACTAAAG          (SEQ ID NO: 16)T7             AATACGACTCACTATAG          (SEQ ID NO: 17)______________________________________</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">              TABLE 15______________________________________MOUSE HEAVY AND LIGHT CHAIN PCR PRIMERS de- scrip-primer tion    nucleotide sequence (5' to 3')______________________________________AB-25 5' VL   GTGCCAGATGTGAGCTCGTGATGACCC kappa   AGTCTCCA         (SEQ ID NO: 10)AB-26 3' CL   TCCTTCTAGATTACTAACACTCTCCCCT kappa   GTTGAA         (SEQ ID NO: 18)AB-28 5' VL   CTGCACAGGGTCCTGGGCCGAGCTCGT lambda  GGTGACTCAG         (SEQ ID NO: 19)AB-92 3' VL   GCATTCTAGACTATTAACATTCTGTAGG lambda  GGC         (SEQ ID NO: 20)AB-19 5' VH   AGGTCCAGCTGCTCGAGTCTGG         (SEQ ID NO: 21)AB-41 3' CH1  AGGCTTACTAGTACAATCCCTGGGCAC         AAT         (SEQ ID NO: 22)MK-   3' VH   CCGTTACTAGTAGCCAAAACGACACCC501           CCATCTGTC         (SEQ ID NO: 23)______________________________________</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">                                  TABLE 16__________________________________________________________________________DNA TEMPLATES AND PCR PRIMER SEQUENCES     primer     nucleotide sequencetemplate description     description                (5' to 3')__________________________________________________________________________human     5' Gaucher's                CCTGAGGGCTCCCAGAGAGT     disease    GG                (SEQ ID NO: 24)human     3' Gaucher's disease                GGTTTAGCACGACCACAACA                GC                (SEQ ID NO: 25)pBluescript KS+     5' multiple cloning                ATTAACCCTCACTAAA     site       (SEQ ID NO: 26)pBluescript KS+     3' multiple cloning                AATACGACTCACTATAG     site       (SEQ ID NO: 27)Epstein Barr virus     5' nuc antigen gene                GGCTGGTGTCACCTGTGTTA                (SEQ ID NO: 28)Epstein Barr virus     3' nuc antigen gene                CCTTAGGAGGAACAAGTCCC                (SEQ ID NO: 29)E. coli   5' RNase H gene                CTTGAAGATCTATGCTTAAA                CAGGTAG                (SEQ ID NO: 30)E. coli   3' RNase H gene                CATGTGAATTCTTAAACTTC                AACTTGG                (SEQ ID NO: 31)transgenic mouse     5' lambda lacZ insert                GGTGGCGACGACTCCTGGAG                CCC                (SEQ ID NO: 32)transgenic mouse     3' lambda lacZ insert                GACAGTCACTCCGGCCCGTG                CGG                (SEQ ID NO: 33)human     5' fucosidase gene                AAGCTTCAGGAAAACAGTG                AGCAGCGCCTC                (SEQ ID NO: 34)human     3' fucosidase gene                AGTCAGGTATCTTTGACAGT                (SEQ ID NO: 35)nontransgenic     5' B-adrenergic                GGAATTCGTAACAGCACTTAmouse     receptor   CGGTAGC                (SEQ ID NO: 36)nontransgenic     3' B-adrenergic                AGCACTCATAAGTGACACCCmouse     receptor   (SEQ ID NO: 37)transgenic mouse     5' lambda lacI insert                CATAGCGAATTCGCAAAACC                TTTCGCGGTATGG                (SEQ ID NO: 38)transgenic mouse     3' lambda lacI insert                ACTACGGAATTCCACGGAAA                ATGCCGCTCATCC                (SEQ ID NO: 39)__________________________________________________________________________</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">              TABLE 17______________________________________10× PCR BUFFER COMPONENTScomponent  Taq      V25       Pfu #1 Pfu #3______________________________________KCl        500 mM   100 mM    100 Mm 100 mM(NH<sub>4</sub>)<sub>2</sub> SO<sub>4</sub>               60 mM     60 mM  100 mMtris-Cl, pH 8.8      100 mMtris-Cl, pH 8.2     200 mM    200 mMtris-Cl, pH 8.5                      200 mMMgCl2      15 mM    15 mM     20 mM  15 mMMgSO4                                20 mMTriton X-100        1% (v/v)  1% (v/v)                                1% (v/v)bovine serum        100       100    1albumin             μg/ml  μg/ml                                mg/mlgelatin    0.01%      (w/v)______________________________________</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">              TABLE 18______________________________________HUMAN VH PCR PRIMERSprimer description            nucleotide sequence (5' to 3')______________________________________AB-61  5' VH     AGGTGCAGCTGCTCGAGTCTGG            (SEQ ID NO: 2)AB-62  5' VH     AGGTGCAGCTGCTCGAGTCGGG            (SEQ ID NO: 40)AB-63  5' VH     AGGTGCAACTGCTCGAGTCTGG            (SEQ ID NO: 41)AB-64  5' VH     AGGTGCAACTGCTCGAGTCGGG            (SEQ ID NO: 42)______________________________________</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">                                  TABLE 19__________________________________________________________________________OLIGONUCLEOTIDE PRIMERS USED TO CONSTRUCTTHE IZ H-8 (-1 to 50) VECTOR__________________________________________________________________________5' cpVIIITTGACTCGAGTAATCTGAGCTAAAGTCTAGAGCGCTGAGGGTGACGATCC(SEQ ID NO: 43)3' cpVIIIATGGCAACTAGTTATCAGCTTGCTTTCGAGG(SEQ ID NO: 44)__________________________________________________________________________</pre>
    
    <heading>EQUIVALENTS</heading> <p>All publications and patent applications mentioned in this specification are indicative of the level of skill of those skilled in the art to which this invention pertains. All publications and patent applications are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.</p>
    <p>The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the invention. Indeed, various modifications of the above-described modes for carrying out the invention which are obvious to those skilled in the field of molecular biology or related fields are intended to be within the scope of the following claims.</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">__________________________________________________________________________SEQUENCE LISTING(1) GENERAL INFORMATION:(iii) NUMBER OF SEQUENCES: 44(2) INFORMATION FOR SEQ ID NO:1:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 32 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:GTCCTGTCCGAGGTGCAGCTGCTCGAGTCTGG32(2) INFORMATION FOR SEQ ID NO:2:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 22 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:AGGTGCAGCTGCTCGAGTCTGG22(2) INFORMATION FOR SEQ ID NO:3:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 22 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:AGGTGCAGCTGCTCGAGTCTGT22(2) INFORMATION FOR SEQ ID NO:4:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 22 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:AGGTGCAGCTGCTCGAGTCTTT22(2) INFORMATION FOR SEQ ID NO:5:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 23 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:AGGTGCAGCTGCTCGAGTCTGGT23(2) INFORMATION FOR SEQ ID NO:6:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 23 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:AGGTGCAGCTGCTCGAGTCTGTT23(2) INFORMATION FOR SEQ ID NO:7:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 27 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:AGCATCACTAGTACAAGATTTGGGCTC27(2) INFORMATION FOR SEQ ID NO:8:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 23 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:CGGGAGATCATGAGGGTGTCCTT23(2) INFORMATION FOR SEQ ID NO:9:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 39 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:ATATACTAGTGAGACAGTGACCAGGGTTCCTTGGCCCCA39(2) INFORMATION FOR SEQ ID NO:10:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 35 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:GTGCCAGATGTGAGCTCGTGATGACCCAGTCTCCA35(2) INFORMATION FOR SEQ ID NO:11:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 56 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:TCCTTCTAGATTACTAACACTCTCCCCTGTTGAAGCTCTTTGTGACGGGCGAACTC56(2) INFORMATION FOR SEQ ID NO:12:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 33 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:GTCTCACTAGTCTCCACCAAGGGCCCATCGGTC33(2) INFORMATION FOR SEQ ID NO:13:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 23 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:CGGGAGATCATGAGGGTGTCCTT23(2) INFORMATION FOR SEQ ID NO:14:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 19 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:CTCAGTATGGTGGTTGTGC19(2) INFORMATION FOR SEQ ID NO:15:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 27 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:CCGGAATTCTTATCATTTACCCGGAGA27(2) INFORMATION FOR SEQ ID NO:16:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 17 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:ATTAACCCTCACTAAAG17(2) INFORMATION FOR SEQ ID NO:17:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 17 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:AATACGACTCACTATAG17(2) INFORMATION FOR SEQ ID NO:18:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 34 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:TCCTTCTAGATTACTAACACTCTCCCCTGTTGAA34(2) INFORMATION FOR SEQ ID NO:19:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 37 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:CTGCACAGGGTCCTGGGCCGAGCTCGTGGTGACTCAG37(2) INFORMATION FOR SEQ ID NO:20:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 31 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:GCATTCTAGACTATTAACATTCTGTAGGGGC31(2) INFORMATION FOR SEQ ID NO:21:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 22 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:AGGTCCAGCTGCTCGAGTCTGG22(2) INFORMATION FOR SEQ ID NO:22:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 30 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:AGGCTTACTAGTACAATCCCTGGGCACAAT30(2) INFORMATION FOR SEQ ID NO:23:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 36 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:CCGTTACTAGTAGCCAAAACGACACCCCCATCTGTC36(2) INFORMATION FOR SEQ ID NO:24:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 22 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:CCTGAGGGCTCCCAGAGAGTGG22(2) INFORMATION FOR SEQ ID NO:25:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 22 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:GGTTTAGCACGACCACAACAGC22(2) INFORMATION FOR SEQ ID NO:26:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 17 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:AATACGACTCACTATAG17(2) INFORMATION FOR SEQ ID NO:27:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 17 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:AATACGACTCACTATAG17(2) INFORMATION FOR SEQ ID NO:28:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:GGCTGGTGTCACCTGTGTTA20(2) INFORMATION FOR SEQ ID NO:29:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:CCTTAGGAGGAACAAGTCCC20(2) INFORMATION FOR SEQ ID NO:30:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 27 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:CTTGAAGATCTATGCTTAAACAGGTAG27(2) INFORMATION FOR SEQ ID NO:31:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 27 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:CATGTGAATTCTTAAACTTCAACTTGG27(2) INFORMATION FOR SEQ ID NO:32:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 23 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:GGTGGCGACGACTCCTGGAGCCC23(2) INFORMATION FOR SEQ ID NO:33:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 23 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:GACAGTCACTCCGGCCCGTGCGG23(2) INFORMATION FOR SEQ ID NO:34:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 30 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:AAGCTTCAGGAAAACAGTGAGCAGCGCCTC30(2) INFORMATION FOR SEQ ID NO:35:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:AGTCAGGTATCTTTGACAGT20(2) INFORMATION FOR SEQ ID NO:36:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 27 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:GGAATTCGTAACAGCACTTACGGTAGC27(2) INFORMATION FOR SEQ ID NO:37:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:AGCACTCATAAGTGACACCC20(2) INFORMATION FOR SEQ ID NO:38:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 33 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:CATAGCGAATTCGCAAAACCTTTCGCGGTATGG33(2) INFORMATION FOR SEQ ID NO:39:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 33 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:ACTACGGAATTCCACGGAAAATGCCGCTCATCC33(2) INFORMATION FOR SEQ ID NO:40:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 22 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:AGGTGCAGCTGCTCGAGTCGGG22(2) INFORMATION FOR SEQ ID NO:41:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 22 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:AGGTGCAACTGCTCGAGTCTGG22(2) INFORMATION FOR SEQ ID NO:42:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 22 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:AGGTGCAACTGCTCGAGTCGGG22(2) INFORMATION FOR SEQ ID NO:43:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 50 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO(xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:TTGACTCGAGTAATCTGAGCTAAAGTCTAGAGCGCTGAGGGTGACGATCC50(2) INFORMATION FOR SEQ ID NO:44:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 31 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO(xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:ATGGCAACTAGTTATCAGCTTGCTTTCGAGG31__________________________________________________________________________</pre>
    
    </div></div></div><div class="patent-section patent-tabular-section"><a id="backward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Cited Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5436149">US5436149</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Feb 19, 1993</td><td class="patent-data-table-td patent-date-value">Jul 25, 1995</td><td class="patent-data-table-td ">Barnes; Wayne M.</td><td class="patent-data-table-td ">Thermostable DNA polymerase with enhanced thermostability and enhanced length and efficiency of primer extension</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0502589A2?cl=en">EP0502589A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Mar 27, 1986</td><td class="patent-data-table-td patent-date-value">Sep 9, 1992</td><td class="patent-data-table-td ">F. Hoffmann-La Roche Ag</td><td class="patent-data-table-td ">Kit for use in amplifying and detecting nucleic acid sequences</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1992009689A1?cl=en">WO1992009689A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Dec 3, 1991</td><td class="patent-data-table-td patent-date-value">Jun 11, 1992</td><td class="patent-data-table-td ">Stratagene Inc</td><td class="patent-data-table-td ">PURIFIED THERMOSTABLE $i(PYROCOCCUS FURIOSUS)</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="npl-citations"></a><div class="patent-section-header"><span class="patent-section-title">Non-Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th colspan="3"class="patent-data-table-th">Reference</th></tr></thead><tr><td class="patent-data-table-td ">1</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Clark, J. M. et al. "<a href='http://scholar.google.com/scholar?q="Novel+Blunt-end+Addition+Reactions+Catalyzed+by+DNA+Polymerase+I+of+Escherichia+Coli"'>Novel Blunt-end Addition Reactions Catalyzed by DNA Polymerase I of Escherichia Coli</a>". Journal of Molecular Biology 198:123-127 (1987).</td></tr><tr><td class="patent-data-table-td ">2</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Clark, J. M. et al. Novel Blunt end Addition Reactions Catalyzed by DNA Polymerase I of Escherichia Coli . Journal of Molecular Biology 198:123 127 (1987).</td></tr><tr><td class="patent-data-table-td ">3</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Clark, James M. "<a href='http://scholar.google.com/scholar?q="Novel+non-templated+nucleotide+addition+reactions+catalyzed+by+procaryotic+and+eucaryotic+DNA+polymerases"'>Novel non-templated nucleotide addition reactions catalyzed by procaryotic and eucaryotic DNA polymerases</a>". Nucleic Acids Research 16:9677-9686 (1988).</td></tr><tr><td class="patent-data-table-td ">4</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Clark, James M. Novel non templated nucleotide addition reactions catalyzed by procaryotic and eucaryotic DNA polymerases . Nucleic Acids Research 16:9677 9686 (1988).</td></tr><tr><td class="patent-data-table-td ">5</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Deng, Win Ping and Nickoloff, Jac A. "<a href='http://scholar.google.com/scholar?q="Site-Directed+Mutagenesis+of+Virtually+Any+Plasmid+by+Eliminating+a+Unique+Site"'>Site-Directed Mutagenesis of Virtually Any Plasmid by Eliminating a Unique Site</a>". Analytical Biochemistry 200:81-88 (1992).</td></tr><tr><td class="patent-data-table-td ">6</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Deng, Win Ping and Nickoloff, Jac A. Site Directed Mutagenesis of Virtually Any Plasmid by Eliminating a Unique Site . Analytical Biochemistry 200:81 88 (1992).</td></tr><tr><td class="patent-data-table-td ">7</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Hall, Len and Emery, David C. "<a href='http://scholar.google.com/scholar?q="A+rapid+and+efficient+method+for+site-directed+mutagenesis+by+PCR%2C+using+biotinylated+universal+primers+and+streptavidin-coated+magnetic+beads"'>A rapid and efficient method for site-directed mutagenesis by PCR, using biotinylated universal primers and streptavidin-coated magnetic beads</a>". Protein Engineering 4(5):601.</td></tr><tr><td class="patent-data-table-td ">8</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Hall, Len and Emery, David C. A rapid and efficient method for site directed mutagenesis by PCR, using biotinylated universal primers and streptavidin coated magnetic beads . Protein Engineering 4(5):601.</td></tr><tr><td class="patent-data-table-td ">9</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Hemsley, Anne et al. "<a href='http://scholar.google.com/scholar?q="A+simple+method+for+site-directed+mutagenesis+using+the+polymerase+using+the+polymerase+chain+reaction"'>A simple method for site-directed mutagenesis using the polymerase using the polymerase chain reaction</a>". Nucleic Acids Research 17(16):6545-6551 (1989).</td></tr><tr><td class="patent-data-table-td ">10</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Hemsley, Anne et al. A simple method for site directed mutagenesis using the polymerase using the polymerase chain reaction . Nucleic Acids Research 17(16):6545 6551 (1989).</td></tr><tr><td class="patent-data-table-td ">11</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Ho, Steffan N. et al. "<a href='http://scholar.google.com/scholar?q="Site-directed+mutagenesis+by+overlap+extension+using+the+polymerase+chain+reaction"'>Site-directed mutagenesis by overlap extension using the polymerase chain reaction</a>". Gene 77(1):51-59 (1989).</td></tr><tr><td class="patent-data-table-td ">12</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Ho, Steffan N. et al. Site directed mutagenesis by overlap extension using the polymerase chain reaction . Gene 77(1):51 59 (1989).</td></tr><tr><td class="patent-data-table-td ">13</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Hu, Gengxi. "<a href='http://scholar.google.com/scholar?q="DNA+Polymerase-Catalyzed+Addition+of+Nontemplated+Extra+Nucleotides+to+the+3%27+End+of+a+DNA+Fragment"'>DNA Polymerase-Catalyzed Addition of Nontemplated Extra Nucleotides to the 3' End of a DNA Fragment</a>". DNA and Cell Biology 12(8):763-770 (1993).</td></tr><tr><td class="patent-data-table-td ">14</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Hu, Gengxi. DNA Polymerase Catalyzed Addition of Nontemplated Extra Nucleotides to the 3 End of a DNA Fragment . DNA and Cell Biology 12(8):763 770 (1993).</td></tr><tr><td class="patent-data-table-td ">15</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Hultman, Thomas et al. "<a href='http://scholar.google.com/scholar?q="Solid+phase+in+vitro+mutagenesis+using+plasmid+DNA+template"'>Solid phase in vitro mutagenesis using plasmid DNA template</a>". Nucleic Acids Research 18(17):5107-5111 (1990).</td></tr><tr><td class="patent-data-table-td ">16</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Hultman, Thomas et al. Solid phase in vitro mutagenesis using plasmid DNA template . Nucleic Acids Research 18(17):5107 5111 (1990).</td></tr><tr><td class="patent-data-table-td ">17</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Jones, C. H. et al. "<a href='http://scholar.google.com/scholar?q="DNA+mutagenesis+and+recombination"'>DNA mutagenesis and recombination</a>". Nature 344(6268):793-794 (1990).</td></tr><tr><td class="patent-data-table-td ">18</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Jones, C. H. et al. DNA mutagenesis and recombination . Nature 344(6268):793 794 (1990).</td></tr><tr><td class="patent-data-table-td ">19</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Jones, Douglas H. and Winistorfer, Stanley C. "<a href='http://scholar.google.com/scholar?q="Recombinant+Circle+PCR+and+Recomination+PCR+for+Site-Specific+Mutagenesis+Without+PCR+Product+Purification"'>Recombinant Circle PCR and Recomination PCR for Site-Specific Mutagenesis Without PCR Product Purification</a>". BioTechniques 12(4):528-533 (1992).</td></tr><tr><td class="patent-data-table-td ">20</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Jones, Douglas H. and Winistorfer, Stanley C. Recombinant Circle PCR and Recomination PCR for Site Specific Mutagenesis Without PCR Product Purification . BioTechniques 12(4):528 533 (1992).</td></tr><tr><td class="patent-data-table-td ">21</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Kunkel, Thomas A. "<a href='http://scholar.google.com/scholar?q="Rapid+and+efficient+site-specific+mutagenesis+without+phenotypic+selection"'>Rapid and efficient site-specific mutagenesis without phenotypic selection</a>". Proceedings of the National Academy of Sciences, USA 82:488-492 (1985).</td></tr><tr><td class="patent-data-table-td ">22</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Kunkel, Thomas A. Rapid and efficient site specific mutagenesis without phenotypic selection . Proceedings of the National Academy of Sciences, USA 82:488 492 (1985).</td></tr><tr><td class="patent-data-table-td ">23</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Landt, Olfert et al. "<a href='http://scholar.google.com/scholar?q="A+general+method+for+rapid+site-directed+mutagenesis+using+the+plymerase+chain+reaction"'>A general method for rapid site-directed mutagenesis using the plymerase chain reaction</a>". Gene 96:125-128 (1990).</td></tr><tr><td class="patent-data-table-td ">24</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Landt, Olfert et al. A general method for rapid site directed mutagenesis using the plymerase chain reaction . Gene 96:125 128 (1990).</td></tr><tr><td class="patent-data-table-td ">25</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Nassal, Michael and Rieger, Andrea. "<a href='http://scholar.google.com/scholar?q="PCR-based+site-directed+mutagenesis+using+primers+with+mismatched+3%27-ends"'>PCR-based site-directed mutagenesis using primers with mismatched 3'-ends</a>".</td></tr><tr><td class="patent-data-table-td ">26</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Nassal, Michael and Rieger, Andrea. PCR based site directed mutagenesis using primers with mismatched 3 ends .</td></tr><tr><td class="patent-data-table-td ">27</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Nelson, Richard M. and Long, George L. "<a href='http://scholar.google.com/scholar?q="A+General+Method+of+Site-Specific+Mutagenesis+Using+a+Modification+of+the+Thermus+aquaticus+Polymerase+Chain+Reaction"'>A General Method of Site-Specific Mutagenesis Using a Modification of the Thermus aquaticus Polymerase Chain Reaction</a>". Analytical Biochemistry 180:147-151 (1989).</td></tr><tr><td class="patent-data-table-td ">28</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Nelson, Richard M. and Long, George L. A General Method of Site Specific Mutagenesis Using a Modification of the Thermus aquaticus Polymerase Chain Reaction . Analytical Biochemistry 180:147 151 (1989).</td></tr><tr><td class="patent-data-table-td ">29</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Othler et al PCR Method &amp; Applications 2:51 59 (1992).</td></tr><tr><td class="patent-data-table-td ">30</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Othler et al PCR Method &amp; Applications 2:51-59 (1992).</td></tr><tr><td class="patent-data-table-td ">31</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Taylor, John W. et al. "<a href='http://scholar.google.com/scholar?q="The+rapid+generation+of+oligonucleotide-directed+mutations+at+high+frequency+using+phosphorothioate-modified+DNA"'>The rapid generation of oligonucleotide-directed mutations at high frequency using phosphorothioate-modified DNA</a>". Nucleic Acids Research 13(24):8765-8775 (1985).</td></tr><tr><td class="patent-data-table-td ">32</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Taylor, John W. et al. The rapid generation of oligonucleotide directed mutations at high frequency using phosphorothioate modified DNA . Nucleic Acids Research 13(24):8765 8775 (1985).</td></tr><tr><td class="patent-data-table-td ">33</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Vallete, Francois et al. "<a href='http://scholar.google.com/scholar?q="Construction+of+mutant+and+chimeric+genes+using+the+poymerase+chain+reaction"'>Construction of mutant and chimeric genes using the poymerase chain reaction</a>", Nucleic Acids Research 17(2):723-733 (1989).</td></tr><tr><td class="patent-data-table-td ">34</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Vallete, Francois et al. Construction of mutant and chimeric genes using the poymerase chain reaction , Nucleic Acids Research 17(2):723 733 (1989).</td></tr><tr><td class="patent-data-table-td ">35</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Vandeyar, Mark A. et al. "<a href='http://scholar.google.com/scholar?q="A+simple+and+rapid+method+for+the+selection+of+oligodeoxynucletide-directed+mutants"'>A simple and rapid method for the selection of oligodeoxynucletide-directed mutants</a>". Gene 65:129-133 (1989).</td></tr><tr><td class="patent-data-table-td ">36</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Vandeyar, Mark A. et al. A simple and rapid method for the selection of oligodeoxynucletide directed mutants . Gene 65:129 133 (1989).</td></tr><tr><td class="patent-data-table-td ">37</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Watkins, Brynmor A. et al. "<a href='http://scholar.google.com/scholar?q="A+Rapid+Method+for+Site-Specific+Mutagenesis+Using+Larger+Plasmids+as+Templates"'>A Rapid Method for Site-Specific Mutagenesis Using Larger Plasmids as Templates</a>". BioTechniques 15(4):700-704 (1993).</td></tr><tr><td class="patent-data-table-td ">38</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Watkins, Brynmor A. et al. A Rapid Method for Site Specific Mutagenesis Using Larger Plasmids as Templates . BioTechniques 15(4):700 704 (1993).</td></tr><tr><td class="patent-data-table-td ">39</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Weiner, Michael P. et al. "<a href='http://scholar.google.com/scholar?q="A+method+for+the+site-directed+mono-+and+multi-mutagenesis+of+double-stranded+DNA"'>A method for the site-directed mono- and multi-mutagenesis of double-stranded DNA</a>". Gene 126:35-41 (1993).</td></tr><tr><td class="patent-data-table-td ">40</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Weiner, Michael P. et al. A method for the site directed mono and multi mutagenesis of double stranded DNA . Gene 126:35 41 (1993).</td></tr><tr><td class="patent-data-table-td ">41</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Yao, Zhengbin et al. "<a href='http://scholar.google.com/scholar?q="Site-directed+Mutagenesis+of+Herpesvirus+Glycoprotein+Phosphorylation+Sites+by+Recombination+Polymerase+Chain+Reaction"'>Site-directed Mutagenesis of Herpesvirus Glycoprotein Phosphorylation Sites by Recombination Polymerase Chain Reaction</a>". PCR Methods and Applications 1(3):205-207 (1992).</td></tr><tr><td class="patent-data-table-td ">42</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Yao, Zhengbin et al. Site directed Mutagenesis of Herpesvirus Glycoprotein Phosphorylation Sites by Recombination Polymerase Chain Reaction . PCR Methods and Applications 1(3):205 207 (1992).</td></tr><tr><td class="patent-data-table-td ">43</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Zhu, Yu Sheng et al. "<a href='http://scholar.google.com/scholar?q="The+use+of+exonuclease+III+for+polymerase+chain+reaction+sterilization"'>The use of exonuclease III for polymerase chain reaction sterilization</a>". Nucleic Acids Research 19(9):2511 (1991).</td></tr><tr><td class="patent-data-table-td ">44</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Zhu, Yu Sheng et al. The use of exonuclease III for polymerase chain reaction sterilization . Nucleic Acids Research 19(9):2511 (1991).</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="forward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Referenced by</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Citing Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6008025">US6008025</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jul 29, 1997</td><td class="patent-data-table-td patent-date-value">Dec 28, 1999</td><td class="patent-data-table-td ">Toyo Boseki Kabushiki Kaisha</td><td class="patent-data-table-td ">A mutated polymerase having lower exonuclease activity and an extension rate of at least 30 bases/second at optimum temperature of about 75 degrees celsius while maintaining its residual activity at ph 8.8; improved dna amplification</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6107032">US6107032</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Dec 16, 1997</td><td class="patent-data-table-td patent-date-value">Aug 22, 2000</td><td class="patent-data-table-td ">Roche Diagnostics Gmbh</td><td class="patent-data-table-td ">Sequence determination of nucleic acid molecule; one step amplification of both full-length and truncated copies of nucleotide sequence, generating a sequence ladder, evaluating sequence patterns to obtain the nucleotide sequence</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6117679">US6117679</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Mar 25, 1996</td><td class="patent-data-table-td patent-date-value">Sep 12, 2000</td><td class="patent-data-table-td ">Maxygen, Inc.</td><td class="patent-data-table-td ">Adjusting polynucleotide sequences; amplifying nucleotide sequences and screening a recombinant polynucleotide for a desired property</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6130045">US6130045</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 11, 1998</td><td class="patent-data-table-td patent-date-value">Oct 10, 2000</td><td class="patent-data-table-td ">Clontech Laboratories, Inc.</td><td class="patent-data-table-td ">Thermostable polymerase</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6132970">US6132970</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 19, 1998</td><td class="patent-data-table-td patent-date-value">Oct 17, 2000</td><td class="patent-data-table-td ">Maxygen, Inc.</td><td class="patent-data-table-td ">Rearranging nucleotide sequences; extending chains of nucleotide sequence with regions of both homogeneity and heterogeneity in multiple cycles, screening rearranged nucleotide sequences to detect desired properties</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6153410">US6153410</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Aug 4, 1997</td><td class="patent-data-table-td patent-date-value">Nov 28, 2000</td><td class="patent-data-table-td ">California Institute Of Technology</td><td class="patent-data-table-td ">Recombination of polynucleotide sequences using random or defined primers</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6165793">US6165793</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">May 8, 1998</td><td class="patent-data-table-td patent-date-value">Dec 26, 2000</td><td class="patent-data-table-td ">Maxygen, Inc.</td><td class="patent-data-table-td ">Methods for generating polynucleotides having desired characteristics by iterative selection and recombination</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6177263">US6177263</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jul 14, 1999</td><td class="patent-data-table-td patent-date-value">Jan 23, 2001</td><td class="patent-data-table-td ">California Institute Of Technology</td><td class="patent-data-table-td ">Simple and efficient method for in vitro mutagenesis and recombination of polynucleotide sequences based on based on polymerase-catalyzed extension of primer oligonucleotides</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6180406">US6180406</a></td><td class="patent-data-table-td patent-date-value">Jun 17, 1998</td><td class="patent-data-table-td patent-date-value">Jan 30, 2001</td><td class="patent-data-table-td ">Maxygen, Inc.</td><td class="patent-data-table-td ">Methods for generating polynucleotides having desired characteristics by iterative selection and recombination</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6183997">US6183997</a></td><td class="patent-data-table-td patent-date-value">Mar 21, 1997</td><td class="patent-data-table-td patent-date-value">Feb 6, 2001</td><td class="patent-data-table-td ">Stratagene</td><td class="patent-data-table-td ">Polymerase enhancing factor (PEF) extracts PEF protein complexes isolated PEF proteins and methods for purifying and identifying same</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6204025">US6204025</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Sep 28, 1998</td><td class="patent-data-table-td patent-date-value">Mar 20, 2001</td><td class="patent-data-table-td ">City Of Hope</td><td class="patent-data-table-td ">Linking dna segments which are partially complementary to each other and which occur in non-adjacent portions of target dna by using polymerase chain reaction; using several polymerases, one which lacks 3&#39; to 5&#39; exonuclease activity</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6218123">US6218123</a></td><td class="patent-data-table-td patent-date-value">Aug 10, 1999</td><td class="patent-data-table-td patent-date-value">Apr 17, 2001</td><td class="patent-data-table-td ">Lexicon Genetics Incorporated</td><td class="patent-data-table-td ">Construction of normalized cDNA libraries from eucaryotic cells</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6225092">US6225092</a></td><td class="patent-data-table-td patent-date-value">Dec 16, 1997</td><td class="patent-data-table-td patent-date-value">May 1, 2001</td><td class="patent-data-table-td ">Roche Diagnostics Gmbh</td><td class="patent-data-table-td ">One step, one pot process using a second thermostable dna polymerase which has a reduced ability to incorporate dideoxynucleotides</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6277638">US6277638</a></td><td class="patent-data-table-td patent-date-value">Jan 15, 1999</td><td class="patent-data-table-td patent-date-value">Aug 21, 2001</td><td class="patent-data-table-td ">Maxygen, Inc.</td><td class="patent-data-table-td ">Producing nucleic acid fragments or polynucleotides conferring desired phenotype which encodes mutant proteins via repeated cycles of in vitro or in vivo recombination (mutagenesis, shuffling, and selection)</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6287861">US6287861</a></td><td class="patent-data-table-td patent-date-value">Aug 12, 1998</td><td class="patent-data-table-td patent-date-value">Sep 11, 2001</td><td class="patent-data-table-td ">Maxygen, Inc.</td><td class="patent-data-table-td ">Methods for generating polynucleotides having desired characteristics by iterative selection and recombination</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6297053">US6297053</a></td><td class="patent-data-table-td patent-date-value">Feb 10, 2000</td><td class="patent-data-table-td patent-date-value">Oct 2, 2001</td><td class="patent-data-table-td ">Maxygen, Inc.</td><td class="patent-data-table-td ">Methods for generating polynucleotides having desired characteristics by iterative selection and recombination</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6303344">US6303344</a></td><td class="patent-data-table-td patent-date-value">Jun 24, 1999</td><td class="patent-data-table-td patent-date-value">Oct 16, 2001</td><td class="patent-data-table-td ">Maxygen, Inc.</td><td class="patent-data-table-td ">Methods and compositions for polypeptide engineering</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6309883">US6309883</a></td><td class="patent-data-table-td patent-date-value">Jan 24, 2000</td><td class="patent-data-table-td patent-date-value">Oct 30, 2001</td><td class="patent-data-table-td ">Maxygen, Inc.</td><td class="patent-data-table-td ">Methods and compositions for cellular and metabolic engineering</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6319713">US6319713</a></td><td class="patent-data-table-td patent-date-value">Jun 25, 1999</td><td class="patent-data-table-td patent-date-value">Nov 20, 2001</td><td class="patent-data-table-td ">Maxygen, Inc.</td><td class="patent-data-table-td ">Methods and compositions for polypeptide engineering</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6323030">US6323030</a></td><td class="patent-data-table-td patent-date-value">Jan 29, 1999</td><td class="patent-data-table-td patent-date-value">Nov 27, 2001</td><td class="patent-data-table-td ">Maxygen, Inc.</td><td class="patent-data-table-td ">Methods for generating polynucleotides having desired characteristics by iterative selection and recombination</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6333165">US6333165</a></td><td class="patent-data-table-td patent-date-value">Aug 4, 2000</td><td class="patent-data-table-td patent-date-value">Dec 25, 2001</td><td class="patent-data-table-td ">Stratagene</td><td class="patent-data-table-td ">Determining if an archaebacteria protein has increased polymerase activity by mixing the protein extracts of pyrococcus furiosus cells into a nucleic acid polymerization reation and measuring the concentration</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6335160">US6335160</a></td><td class="patent-data-table-td patent-date-value">Dec 18, 1996</td><td class="patent-data-table-td patent-date-value">Jan 1, 2002</td><td class="patent-data-table-td ">Maxygen, Inc.</td><td class="patent-data-table-td ">Methods and compositions for polypeptide engineering</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6344356">US6344356</a></td><td class="patent-data-table-td patent-date-value">Jun 8, 2000</td><td class="patent-data-table-td patent-date-value">Feb 5, 2002</td><td class="patent-data-table-td ">Maxygen, Inc.</td><td class="patent-data-table-td ">Methods for recombining nucleic acids</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6355484">US6355484</a></td><td class="patent-data-table-td patent-date-value">Jun 24, 1999</td><td class="patent-data-table-td patent-date-value">Mar 12, 2002</td><td class="patent-data-table-td ">Maxygen, Inc.</td><td class="patent-data-table-td ">Methods and compositions for polypeptides engineering</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6365375">US6365375</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Mar 16, 1999</td><td class="patent-data-table-td patent-date-value">Apr 2, 2002</td><td class="patent-data-table-td ">Wolfgang Dietmaier</td><td class="patent-data-table-td ">Method of primer-extension preamplification PCR</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6365408">US6365408</a></td><td class="patent-data-table-td patent-date-value">Jan 4, 2000</td><td class="patent-data-table-td patent-date-value">Apr 2, 2002</td><td class="patent-data-table-td ">Maxygen, Inc.</td><td class="patent-data-table-td ">Methods of evolving a polynucleotides by mutagenesis and recombination</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6372497">US6372497</a></td><td class="patent-data-table-td patent-date-value">Jun 8, 2000</td><td class="patent-data-table-td patent-date-value">Apr 16, 2002</td><td class="patent-data-table-td ">Maxygen, Inc.</td><td class="patent-data-table-td ">Methods for generating polynucleotides having desired characteristics by iterative selection and recombination</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6379553">US6379553</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Aug 4, 2000</td><td class="patent-data-table-td patent-date-value">Apr 30, 2002</td><td class="patent-data-table-td ">Stratagene</td><td class="patent-data-table-td ">Solubilizing; heparin sepharose chromatography; detection</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6391640">US6391640</a></td><td class="patent-data-table-td patent-date-value">Nov 9, 1998</td><td class="patent-data-table-td patent-date-value">May 21, 2002</td><td class="patent-data-table-td ">Maxygen, Inc.</td><td class="patent-data-table-td ">Methods and compositions for cellular and metabolic engineering</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6395547">US6395547</a></td><td class="patent-data-table-td patent-date-value">Jul 19, 2000</td><td class="patent-data-table-td patent-date-value">May 28, 2002</td><td class="patent-data-table-td ">Maxygen, Inc.</td><td class="patent-data-table-td ">Methods for generating polynucleotides having desired characteristics by iterative selection and recombination</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6399304">US6399304</a></td><td class="patent-data-table-td patent-date-value">May 24, 2000</td><td class="patent-data-table-td patent-date-value">Jun 4, 2002</td><td class="patent-data-table-td ">Roche Diagnostics Gmbh</td><td class="patent-data-table-td ">Sequential activation of one or more enzymatic activities within a thermocycling reaction for synthesizing DNA molecules</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6406855">US6406855</a></td><td class="patent-data-table-td patent-date-value">Nov 22, 2000</td><td class="patent-data-table-td patent-date-value">Jun 18, 2002</td><td class="patent-data-table-td ">Maxygen, Inc.</td><td class="patent-data-table-td ">Detection of cytokines and nucleic acid subsequences of polynucleotides and injections</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6410277">US6410277</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Sep 16, 1997</td><td class="patent-data-table-td patent-date-value">Jun 25, 2002</td><td class="patent-data-table-td ">Takara Shuzo Co., Ltd.</td><td class="patent-data-table-td ">DNA polymersases with enhanced length of primer extension</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6413774">US6413774</a></td><td class="patent-data-table-td patent-date-value">Jan 29, 1999</td><td class="patent-data-table-td patent-date-value">Jul 2, 2002</td><td class="patent-data-table-td ">Maxygen, Inc.</td><td class="patent-data-table-td ">Producing recombinant nucleic acid using cycles of hybridization, chain extension, and denaturation; then transferring into cells for recombining</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6444428">US6444428</a></td><td class="patent-data-table-td patent-date-value">Aug 4, 2000</td><td class="patent-data-table-td patent-date-value">Sep 3, 2002</td><td class="patent-data-table-td ">Stratagene</td><td class="patent-data-table-td ">Polymerase enhancing factor (PEF) extracts, PEF protein complexes, isolated PEF proteins, and methods for purifying and identifying same</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6444468">US6444468</a></td><td class="patent-data-table-td patent-date-value">Nov 28, 2000</td><td class="patent-data-table-td patent-date-value">Sep 3, 2002</td><td class="patent-data-table-td ">Maxygen, Inc.</td><td class="patent-data-table-td ">Treating a sample comprising different double-stranded template polynucleotides wherein said different template polynucleotides contain areas of identity and areas of heterology under conditions which provide for the cleavage of</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6455253">US6455253</a></td><td class="patent-data-table-td patent-date-value">Apr 27, 2000</td><td class="patent-data-table-td patent-date-value">Sep 24, 2002</td><td class="patent-data-table-td ">Maxygen, Inc.</td><td class="patent-data-table-td ">Methods and compositions for polypeptide engineering</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6495350">US6495350</a></td><td class="patent-data-table-td patent-date-value">Dec 23, 1999</td><td class="patent-data-table-td patent-date-value">Dec 17, 2002</td><td class="patent-data-table-td ">Invitrogen Corporation</td><td class="patent-data-table-td ">Compositions comprising a M-MLV reverse transcriptase and a DNA polymerase and use thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6506602">US6506602</a></td><td class="patent-data-table-td patent-date-value">Oct 25, 2000</td><td class="patent-data-table-td patent-date-value">Jan 14, 2003</td><td class="patent-data-table-td ">Maxygen, Inc.</td><td class="patent-data-table-td ">Methods for generating polynucleotides having desired characteristics by iterative selection and recombination</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6506603">US6506603</a></td><td class="patent-data-table-td patent-date-value">Nov 18, 2000</td><td class="patent-data-table-td patent-date-value">Jan 14, 2003</td><td class="patent-data-table-td ">Maxygen, Inc.</td><td class="patent-data-table-td ">DNA reassembly after random fragmentation; mutagenesis cycles; denaturing, incubation, genetic engineering, screening</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6518019">US6518019</a></td><td class="patent-data-table-td patent-date-value">Feb 5, 1999</td><td class="patent-data-table-td patent-date-value">Feb 11, 2003</td><td class="patent-data-table-td ">Invitrogen Corporation</td><td class="patent-data-table-td ">Enzymatic polypeptide for use as tools in the generation and amplification of preferential nucleotide sequences</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6518065">US6518065</a></td><td class="patent-data-table-td patent-date-value">Oct 25, 2000</td><td class="patent-data-table-td patent-date-value">Feb 11, 2003</td><td class="patent-data-table-td ">Maxygen, Inc.</td><td class="patent-data-table-td ">Methods for generating polynucleotides having desired characteristics by iterative selection and recombination</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6528254">US6528254</a></td><td class="patent-data-table-td patent-date-value">Oct 29, 1999</td><td class="patent-data-table-td patent-date-value">Mar 4, 2003</td><td class="patent-data-table-td ">Stratagene</td><td class="patent-data-table-td ">Incubating with a nucleic acid polymerase to form duplex and single-stranded nucleic acid; cleaving with FEN(5&#39;flap-specific) nuclease to generate a signal</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6537746">US6537746</a></td><td class="patent-data-table-td patent-date-value">Dec 4, 1998</td><td class="patent-data-table-td patent-date-value">Mar 25, 2003</td><td class="patent-data-table-td ">Maxygen, Inc.</td><td class="patent-data-table-td ">Method for creating polynucleotide and polypeptide sequences</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6548250">US6548250</a></td><td class="patent-data-table-td patent-date-value">Aug 30, 2000</td><td class="patent-data-table-td patent-date-value">Apr 15, 2003</td><td class="patent-data-table-td ">Stratagene</td><td class="patent-data-table-td ">Methods for detection of a target nucleic acid sequence</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6573098">US6573098</a></td><td class="patent-data-table-td patent-date-value">Jan 29, 1999</td><td class="patent-data-table-td patent-date-value">Jun 3, 2003</td><td class="patent-data-table-td ">Maxygen, Inc.</td><td class="patent-data-table-td ">Nucleic acid libraries</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6576467">US6576467</a></td><td class="patent-data-table-td patent-date-value">Nov 21, 2000</td><td class="patent-data-table-td patent-date-value">Jun 10, 2003</td><td class="patent-data-table-td ">Maxygen, Inc.</td><td class="patent-data-table-td ">Methods for producing recombined antibodies</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6579678">US6579678</a></td><td class="patent-data-table-td patent-date-value">Oct 20, 2000</td><td class="patent-data-table-td patent-date-value">Jun 17, 2003</td><td class="patent-data-table-td ">Maxygen, Inc.</td><td class="patent-data-table-td ">Identifying evolved polynucleotides using recursive sequence recombination; recombining overlapping nucleotide sequences; screening for desired property; use in correlating different combinations of mutations with a desired result</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6589743">US6589743</a></td><td class="patent-data-table-td patent-date-value">Oct 17, 2001</td><td class="patent-data-table-td patent-date-value">Jul 8, 2003</td><td class="patent-data-table-td ">Stratagene</td><td class="patent-data-table-td ">Methods for detection of a target nucleic acid using a probe comprising secondary structure</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6602986">US6602986</a></td><td class="patent-data-table-td patent-date-value">Nov 15, 2000</td><td class="patent-data-table-td patent-date-value">Aug 5, 2003</td><td class="patent-data-table-td ">Maxygen, Inc.</td><td class="patent-data-table-td ">Antibody comprising a heavy and light chain, each comprising three nonnaturally occuring chain determining regions; antibody specifically binds to human antigen</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6605428">US6605428</a></td><td class="patent-data-table-td patent-date-value">Jun 24, 1999</td><td class="patent-data-table-td patent-date-value">Aug 12, 2003</td><td class="patent-data-table-td ">Roche Diagnostics Gmbh</td><td class="patent-data-table-td ">Method for the direct, exponential amplification and sequencing of DNA molecules and its application</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6613514">US6613514</a></td><td class="patent-data-table-td patent-date-value">Apr 27, 2000</td><td class="patent-data-table-td patent-date-value">Sep 2, 2003</td><td class="patent-data-table-td ">Maxygen, Inc.</td><td class="patent-data-table-td ">Evolving preferential protein; digest nuclelotide sequences substrate, join terminals, screen for preferential proteins, recover nucleotide sequences</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6653072">US6653072</a></td><td class="patent-data-table-td patent-date-value">Jun 24, 1999</td><td class="patent-data-table-td patent-date-value">Nov 25, 2003</td><td class="patent-data-table-td ">Maxygen, Inc.</td><td class="patent-data-table-td ">Improving expression of a protein encoded by DNA substrate by assembling oligonucleotides into recombinant nucleic acids and using it to transform cells; recursive sequence recombination</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6699985">US6699985</a></td><td class="patent-data-table-td patent-date-value">Jan 5, 2001</td><td class="patent-data-table-td patent-date-value">Mar 2, 2004</td><td class="patent-data-table-td ">Arsinur Burcoglu</td><td class="patent-data-table-td ">Administering a defibrotide</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6767724">US6767724</a></td><td class="patent-data-table-td patent-date-value">Aug 21, 2002</td><td class="patent-data-table-td patent-date-value">Jul 27, 2004</td><td class="patent-data-table-td ">Invitrogen Corporation</td><td class="patent-data-table-td ">Replicating nucleotide sequences using moloney murine leukemia virus polymerase; forensics; medical diagnosis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6803216">US6803216</a></td><td class="patent-data-table-td patent-date-value">May 23, 2002</td><td class="patent-data-table-td patent-date-value">Oct 12, 2004</td><td class="patent-data-table-td ">Stratagene California</td><td class="patent-data-table-td ">Compositions and methods for random nucleic acid mutagenesis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6828094">US6828094</a></td><td class="patent-data-table-td patent-date-value">Jun 24, 1999</td><td class="patent-data-table-td patent-date-value">Dec 7, 2004</td><td class="patent-data-table-td ">Roche Diagnostics Gmbh</td><td class="patent-data-table-td ">Method for the uncoupled, direct, exponential amplification and sequencing of DNA molecules with the addition of a second thermostable DNA polymerase and its application</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6946296">US6946296</a></td><td class="patent-data-table-td patent-date-value">Sep 12, 2001</td><td class="patent-data-table-td patent-date-value">Sep 20, 2005</td><td class="patent-data-table-td ">Maxygen, Inc.</td><td class="patent-data-table-td ">Methods and compositions for polypeptide engineering</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6995017">US6995017</a></td><td class="patent-data-table-td patent-date-value">Jan 28, 1999</td><td class="patent-data-table-td patent-date-value">Feb 7, 2006</td><td class="patent-data-table-td ">Maxygen, Inc.</td><td class="patent-data-table-td ">Methods for generating polynucleotides having desired characteristics by iterative selection and recombination</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7070962">US7070962</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jan 30, 1997</td><td class="patent-data-table-td patent-date-value">Jul 4, 2006</td><td class="patent-data-table-td ">Aventis Pharmaceuticals Inc.</td><td class="patent-data-table-td ">Polymerase chain reactions; hybridization; forming copies; process control</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7101872">US7101872</a></td><td class="patent-data-table-td patent-date-value">Jan 21, 2004</td><td class="patent-data-table-td patent-date-value">Sep 5, 2006</td><td class="patent-data-table-td ">Ecopia Biosciences, Inc.</td><td class="patent-data-table-td ">Farnesyl dibenzodiazepinone, and processes for its production</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7105297">US7105297</a></td><td class="patent-data-table-td patent-date-value">Sep 17, 2002</td><td class="patent-data-table-td patent-date-value">Sep 12, 2006</td><td class="patent-data-table-td ">Maxygen, Inc.</td><td class="patent-data-table-td ">Evolution of biocatalytic activity in cell; obtain nucleotide sequences, recombine sequences in gene, transform into cell, monitor cell for novel biocatalytic activity</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7115406">US7115406</a></td><td class="patent-data-table-td patent-date-value">Nov 13, 2002</td><td class="patent-data-table-td patent-date-value">Oct 3, 2006</td><td class="patent-data-table-td ">Invitrogen Corporation</td><td class="patent-data-table-td ">Recombinant method for making RSV reverse transcriptases and mutants thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7166466">US7166466</a></td><td class="patent-data-table-td patent-date-value">Feb 19, 2003</td><td class="patent-data-table-td patent-date-value">Jan 23, 2007</td><td class="patent-data-table-td ">California Institute Of Technology</td><td class="patent-data-table-td ">Method for creating polynucleotide and polypeptide sequences</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7288375">US7288375</a></td><td class="patent-data-table-td patent-date-value">Jul 18, 2003</td><td class="patent-data-table-td patent-date-value">Oct 30, 2007</td><td class="patent-data-table-td ">Maxygen, Inc.</td><td class="patent-data-table-td ">Introducing one or more mutations into a template double-stranded polynucleotide via hybridization, replication and amplification of random genomic double stranded and heterozygous oligonucleotides sequences; genomics and directed evolution</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7297519">US7297519</a></td><td class="patent-data-table-td patent-date-value">Dec 13, 2002</td><td class="patent-data-table-td patent-date-value">Nov 20, 2007</td><td class="patent-data-table-td ">Stratagene California</td><td class="patent-data-table-td ">Polymerase compositions and uses thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7297524">US7297524</a></td><td class="patent-data-table-td patent-date-value">Jan 12, 2006</td><td class="patent-data-table-td patent-date-value">Nov 20, 2007</td><td class="patent-data-table-td ">Thallion Pharmceuticals Inc.</td><td class="patent-data-table-td ">Polynucleotides for production of farnesyl dibenzodiazepinones</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7312052">US7312052</a></td><td class="patent-data-table-td patent-date-value">Sep 18, 1995</td><td class="patent-data-table-td patent-date-value">Dec 25, 2007</td><td class="patent-data-table-td ">Stratagene California</td><td class="patent-data-table-td ">Combination of a thermostable enzyme with substantial 3&#39;-5&#39; exonuclease activity and a DNA polymerase having less 3&#39;-5&#39; exonuclease activity than the enzyme; both the enzyme and the DNA polymerase retain at least 50 % of their specific activity after exposure to 80 degrees Celsius for 20 minutes</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7361467">US7361467</a></td><td class="patent-data-table-td patent-date-value">Jun 10, 2005</td><td class="patent-data-table-td patent-date-value">Apr 22, 2008</td><td class="patent-data-table-td ">Stratagene California</td><td class="patent-data-table-td ">Incubating with a nucleic acid polymerase to form duplex and single-stranded nucleic acid; cleaving with FEN(5&#39;flap-specific) nuclease to generate a signal</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7378262">US7378262</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Dec 11, 2002</td><td class="patent-data-table-td patent-date-value">May 27, 2008</td><td class="patent-data-table-td ">Roche Molecular Systems, Inc.</td><td class="patent-data-table-td ">Reversibly modified thermostable enzymes for DNA synthesis and amplification in vitro</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7452665">US7452665</a></td><td class="patent-data-table-td patent-date-value">Oct 17, 2001</td><td class="patent-data-table-td patent-date-value">Nov 18, 2008</td><td class="patent-data-table-td ">Takara Bio Inc.</td><td class="patent-data-table-td ">DNA polymerases with enhanced length of primer extension</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7482121">US7482121</a></td><td class="patent-data-table-td patent-date-value">Apr 14, 2005</td><td class="patent-data-table-td patent-date-value">Jan 27, 2009</td><td class="patent-data-table-td ">Hologic Inc.</td><td class="patent-data-table-td ">Incubating sample with probe having secondary structure that changes upon binding; nuclease cleavage; releasing signal generating fragment</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7521178">US7521178</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Apr 21, 1999</td><td class="patent-data-table-td patent-date-value">Apr 21, 2009</td><td class="patent-data-table-td ">Takara Bio Inc.</td><td class="patent-data-table-td ">Method for synthesizing DNA</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7521222">US7521222</a></td><td class="patent-data-table-td patent-date-value">Aug 28, 2006</td><td class="patent-data-table-td patent-date-value">Apr 21, 2009</td><td class="patent-data-table-td ">Thallion Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Farnesyl dibenzodiazepinone and processes for its production</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7534568">US7534568</a></td><td class="patent-data-table-td patent-date-value">Nov 30, 2006</td><td class="patent-data-table-td patent-date-value">May 19, 2009</td><td class="patent-data-table-td ">Hologic Inc.</td><td class="patent-data-table-td ">Polymerase, cleavage agent, upstream primer and downstream cleavage resistant probe; kits; incubation, hybridization, cleavage and fluorescent signal measurement</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7553619">US7553619</a></td><td class="patent-data-table-td patent-date-value">Feb 8, 2002</td><td class="patent-data-table-td patent-date-value">Jun 30, 2009</td><td class="patent-data-table-td ">Qiagen Gmbh</td><td class="patent-data-table-td ">For point mutations in small quantities of proteins/peptides</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7618776">US7618776</a></td><td class="patent-data-table-td patent-date-value">Jul 22, 2004</td><td class="patent-data-table-td patent-date-value">Nov 17, 2009</td><td class="patent-data-table-td ">Yale University</td><td class="patent-data-table-td ">Rolling circle replication reporter systems</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7625725">US7625725</a></td><td class="patent-data-table-td patent-date-value">Aug 4, 2000</td><td class="patent-data-table-td patent-date-value">Dec 1, 2009</td><td class="patent-data-table-td ">Stratagene California</td><td class="patent-data-table-td ">Provides novel extracts, proteins, and complexes that improve the polymerization activity of nucleic acid polymerases; specifically described is nucleotide and amino acid sequence information for Pyrococcus furiousus PEF (P45), which was used to produce a recombinant PEF</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7655405">US7655405</a></td><td class="patent-data-table-td patent-date-value">Nov 29, 2006</td><td class="patent-data-table-td patent-date-value">Feb 2, 2010</td><td class="patent-data-table-td ">Hologic, Inc</td><td class="patent-data-table-td ">Generating a signal indicative of the presence of a target nucleic acid in a sequence by incubating the sample containing the target with a reverse transcriptase, a primer and a probe</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7655646">US7655646</a></td><td class="patent-data-table-td patent-date-value">Dec 21, 2007</td><td class="patent-data-table-td patent-date-value">Feb 2, 2010</td><td class="patent-data-table-td ">Thallion Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Antineoplastic agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7736854">US7736854</a></td><td class="patent-data-table-td patent-date-value">Nov 29, 2006</td><td class="patent-data-table-td patent-date-value">Jun 15, 2010</td><td class="patent-data-table-td ">Hologic, Inc.</td><td class="patent-data-table-td ">Methods of detection of a target nucleic acid sequence</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7776598">US7776598</a></td><td class="patent-data-table-td patent-date-value">Feb 5, 2008</td><td class="patent-data-table-td patent-date-value">Aug 17, 2010</td><td class="patent-data-table-td ">Maxygen, Inc.</td><td class="patent-data-table-td ">Methods and compositions for polypeptide engineering</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7790381">US7790381</a></td><td class="patent-data-table-td patent-date-value">Dec 7, 2006</td><td class="patent-data-table-td patent-date-value">Sep 7, 2010</td><td class="patent-data-table-td ">California Institute Of Technology</td><td class="patent-data-table-td ">Method for creating polynucleotide and polypeptide sequences</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7795030">US7795030</a></td><td class="patent-data-table-td patent-date-value">Jan 28, 2008</td><td class="patent-data-table-td patent-date-value">Sep 14, 2010</td><td class="patent-data-table-td ">Maxygen, Inc.</td><td class="patent-data-table-td ">Methods and compositions for cellular and metabolic engineering</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7846661">US7846661</a></td><td class="patent-data-table-td patent-date-value">Nov 29, 2006</td><td class="patent-data-table-td patent-date-value">Dec 7, 2010</td><td class="patent-data-table-td ">Hologic, Inc.</td><td class="patent-data-table-td ">Methods of detecting an amplified nucleic acid</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7855055">US7855055</a></td><td class="patent-data-table-td patent-date-value">Oct 21, 2008</td><td class="patent-data-table-td patent-date-value">Dec 21, 2010</td><td class="patent-data-table-td ">Takara Shuzo Co., Ltd.</td><td class="patent-data-table-td ">Heat resistant polymerases for use as tools in genetic engineering; enzymatic extension of DNA strands; efficiently catalyzing the amplification by PCR (the polymerase chain reaction) of unusually long and faithful products</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7868138">US7868138</a></td><td class="patent-data-table-td patent-date-value">Feb 1, 2008</td><td class="patent-data-table-td patent-date-value">Jan 11, 2011</td><td class="patent-data-table-td ">Codexis, Inc.</td><td class="patent-data-table-td ">mutant green fluorescent protein (GFP) with enhanced fluorescent intensity as compared to wild type Aequorea victoria GFP; use of repeated cycles of mutagenesis, in vivo recombination and selection which allow for the directed molecular evolution in vivo and in vitro of highly complex linear sequences</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7883871">US7883871</a></td><td class="patent-data-table-td patent-date-value">Jun 7, 2004</td><td class="patent-data-table-td patent-date-value">Feb 8, 2011</td><td class="patent-data-table-td ">Life Technologies Corporation</td><td class="patent-data-table-td ">Compositions and methods for reverse transcriptase-polymerase chain reaction (RT-PCR)</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7897738">US7897738</a></td><td class="patent-data-table-td patent-date-value">Dec 9, 2005</td><td class="patent-data-table-td patent-date-value">Mar 1, 2011</td><td class="patent-data-table-td ">Applied Biosystems, Llc</td><td class="patent-data-table-td ">DNA polymerases having improved labeled nucleotide incorporation properties</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7943358">US7943358</a></td><td class="patent-data-table-td patent-date-value">Dec 4, 2006</td><td class="patent-data-table-td patent-date-value">May 17, 2011</td><td class="patent-data-table-td ">Agilent Technologies, Inc.</td><td class="patent-data-table-td ">Polymerase enhancing factor (PEF) extracts, PEF protein complexes, isolated PEF protein, and methods for purifying and identifying</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7960157">US7960157</a></td><td class="patent-data-table-td patent-date-value">Nov 5, 2003</td><td class="patent-data-table-td patent-date-value">Jun 14, 2011</td><td class="patent-data-table-td ">Agilent Technologies, Inc.</td><td class="patent-data-table-td ">DNA polymerase blends and uses thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7972828">US7972828</a></td><td class="patent-data-table-td patent-date-value">Dec 19, 2006</td><td class="patent-data-table-td patent-date-value">Jul 5, 2011</td><td class="patent-data-table-td ">Sigma-Aldrich Co.</td><td class="patent-data-table-td ">a mixture of polymerases and anionic or zwitterionic surfactants, used for protecting DNA during genetic replication</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7981614">US7981614</a></td><td class="patent-data-table-td patent-date-value">Sep 11, 2009</td><td class="patent-data-table-td patent-date-value">Jul 19, 2011</td><td class="patent-data-table-td ">Codexis Mayflower Holdings Llc</td><td class="patent-data-table-td ">Methods for generating polynucleotides having desired characteristics by iterative selection and recombination</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8048674">US8048674</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Sep 11, 2009</td><td class="patent-data-table-td patent-date-value">Nov 1, 2011</td><td class="patent-data-table-td ">Codexis Mayflower Holdings, Llc</td><td class="patent-data-table-td ">Methods and compositions for cellular and metabolic engineering</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8367328">US8367328</a></td><td class="patent-data-table-td patent-date-value">Oct 15, 2008</td><td class="patent-data-table-td patent-date-value">Feb 5, 2013</td><td class="patent-data-table-td ">Takara Bio Inc.</td><td class="patent-data-table-td ">Method for synthesizing DNA</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8372604">US8372604</a></td><td class="patent-data-table-td patent-date-value">Dec 29, 2010</td><td class="patent-data-table-td patent-date-value">Feb 12, 2013</td><td class="patent-data-table-td ">Life Technologies Corporation</td><td class="patent-data-table-td ">Compositions and methods for reverse transcriptase-polymerase chain reaction (RT-PCR)</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8404464">US8404464</a></td><td class="patent-data-table-td patent-date-value">Apr 22, 2011</td><td class="patent-data-table-td patent-date-value">Mar 26, 2013</td><td class="patent-data-table-td ">Sigma-Aldrich Co., Llc</td><td class="patent-data-table-td ">Methods of using stabilized compositions of thermostable DNA polymerase and anionic detergent</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8709724">US8709724</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Nov 7, 2003</td><td class="patent-data-table-td patent-date-value">Apr 29, 2014</td><td class="patent-data-table-td ">President And Fellows Of Harvard College</td><td class="patent-data-table-td ">Isothermal amplification of DNA</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8741560">US8741560</a></td><td class="patent-data-table-td patent-date-value">Jan 6, 2012</td><td class="patent-data-table-td patent-date-value">Jun 3, 2014</td><td class="patent-data-table-td ">Life Technologies Corporation</td><td class="patent-data-table-td ">Stable compositions for nucleic acid amplification and sequencing</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8772006">US8772006</a></td><td class="patent-data-table-td patent-date-value">May 15, 2006</td><td class="patent-data-table-td patent-date-value">Jul 8, 2014</td><td class="patent-data-table-td ">Agilent Technologies, Inc.</td><td class="patent-data-table-td ">Compositions and methods utilizing DNA polymerases</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US20110143399">US20110143399</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jul 15, 2009</td><td class="patent-data-table-td patent-date-value">Jun 16, 2011</td><td class="patent-data-table-td ">University Of Guelph</td><td class="patent-data-table-td ">Dna joining method</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/CN1482240B?cl=en">CN1482240B</a></td><td class="patent-data-table-td patent-date-value">Apr 2, 2003</td><td class="patent-data-table-td patent-date-value">Sep 5, 2012</td><td class="patent-data-table-td ">霍夫曼-拉罗奇有限公司</td><td class="patent-data-table-td ">Thermostable or thermoactive DNA polymerase with attenuated 3&#39;-5&#39; exonuclease activity</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/DE19653494A1?cl=en">DE19653494A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Dec 20, 1996</td><td class="patent-data-table-td patent-date-value">Jun 25, 1998</td><td class="patent-data-table-td ">Svante Dr Paeaebo</td><td class="patent-data-table-td ">Verfahren zur entkoppelten, direkten, exponentiellen Amplifikation und Sequenzierung von DNA Molekülen unter Zugabe einer zweiten thermostabilen DNA Polymerase und dessen Anwendung</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0942917A1?cl=en">EP0942917A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Aug 14, 1997</td><td class="patent-data-table-td patent-date-value">Sep 22, 1999</td><td class="patent-data-table-td ">Life Technologies, Inc.</td><td class="patent-data-table-td ">Stable compositions for nucleic acid amplification and sequencing</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP1072678A1?cl=en">EP1072678A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Apr 21, 1999</td><td class="patent-data-table-td patent-date-value">Jan 31, 2001</td><td class="patent-data-table-td ">Takara Shuzo Co, Ltd.</td><td class="patent-data-table-td ">Method for synthesizing dna</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2110432A2?cl=en">EP2110432A2</a></td><td class="patent-data-table-td patent-date-value">Dec 17, 2002</td><td class="patent-data-table-td patent-date-value">Oct 21, 2009</td><td class="patent-data-table-td ">Stratagene California</td><td class="patent-data-table-td ">High fidelity DNA polymerase compositions and uses therefor</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2115131A2?cl=en">EP2115131A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Dec 18, 2007</td><td class="patent-data-table-td patent-date-value">Nov 11, 2009</td><td class="patent-data-table-td ">Sigma-Aldrich Co.</td><td class="patent-data-table-td ">Stabilized compositions of thermostable dna polymerase and anionic or zwitterionic detergent</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2194123A1?cl=en">EP2194123A1</a></td><td class="patent-data-table-td patent-date-value">Mar 19, 2004</td><td class="patent-data-table-td patent-date-value">Jun 9, 2010</td><td class="patent-data-table-td ">Stratagene California</td><td class="patent-data-table-td ">DNA polymerase fusions and uses thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2272952A1?cl=en">EP2272952A1</a></td><td class="patent-data-table-td patent-date-value">Mar 31, 2003</td><td class="patent-data-table-td patent-date-value">Jan 12, 2011</td><td class="patent-data-table-td ">Roche Diagnostics GmbH</td><td class="patent-data-table-td ">Thermostable or thermoactive DNA polymerase with attenuated 3&#39;-5&#39; exonuclease activity</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2298935A1?cl=en">EP2298935A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 27, 2000</td><td class="patent-data-table-td patent-date-value">Mar 23, 2011</td><td class="patent-data-table-td ">Hologic Inc.</td><td class="patent-data-table-td ">Methods for detection of a target nucleic acid sequence</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1998042860A1?cl=en">WO1998042860A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Mar 20, 1998</td><td class="patent-data-table-td patent-date-value">Oct 1, 1998</td><td class="patent-data-table-td ">Connie J Hansen</td><td class="patent-data-table-td ">Polymerase enhancing factor (pef) extracts, pef protein complexes, isolated pef protein, and methods for purifying and identifying</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1998044161A1?cl=en">WO1998044161A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Apr 3, 1998</td><td class="patent-data-table-td patent-date-value">Oct 8, 1998</td><td class="patent-data-table-td ">Life Technologies Inc</td><td class="patent-data-table-td ">Compositions and methods for reverse transcriptase-polymerase chain reaction (rt-pcr)</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2001032922A2?cl=en">WO2001032922A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 27, 2000</td><td class="patent-data-table-td patent-date-value">May 10, 2001</td><td class="patent-data-table-td ">Stratagene Inc</td><td class="patent-data-table-td ">Methods for detection of a target nucleic acid sequence</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2002064842A2?cl=en">WO2002064842A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Feb 13, 2002</td><td class="patent-data-table-td patent-date-value">Aug 22, 2002</td><td class="patent-data-table-td ">Children S Hospital Res Founda</td><td class="patent-data-table-td ">Quantitative epstein barr virus pcr rapid assay</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2002097078A1?cl=en">WO2002097078A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">May 23, 2002</td><td class="patent-data-table-td patent-date-value">Dec 5, 2002</td><td class="patent-data-table-td ">Janice Marie Cline</td><td class="patent-data-table-td ">Compositions and methods for random nucleic acid mutagenisis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2004058942A2?cl=en">WO2004058942A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Dec 18, 2003</td><td class="patent-data-table-td patent-date-value">Jul 15, 2004</td><td class="patent-data-table-td ">Michael Borns</td><td class="patent-data-table-td ">Dna polymerase blends and uses thereof</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="classifications"></a><div class="patent-section-header"><span class="patent-section-title">Classifications</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th"> </th><th class="patent-data-table-th"> </th></tr></thead><tr><td class="patent-data-table-td ">U.S. Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=805ABAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc435/defs435.htm&usg=AFQjCNFivWgFr8pvtdk7qYLW9R7yxFP7Dg#C435S091200">435/91.2</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=805ABAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc435/defs435.htm&usg=AFQjCNFivWgFr8pvtdk7qYLW9R7yxFP7Dg#C435S091100">435/91.1</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=805ABAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc435/defs435.htm&usg=AFQjCNFivWgFr8pvtdk7qYLW9R7yxFP7Dg#C435S091500">435/91.5</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=805ABAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc435/defs435.htm&usg=AFQjCNFivWgFr8pvtdk7qYLW9R7yxFP7Dg#C435S006180">435/6.18</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=805ABAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc435/defs435.htm&usg=AFQjCNFivWgFr8pvtdk7qYLW9R7yxFP7Dg#C435S006100">435/6.1</a></span></td></tr><tr><td class="patent-data-table-td ">International Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=805ABAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C12Q0001680000">C12Q1/68</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=805ABAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C12N0009120000">C12N9/12</a></span></td></tr><tr><td class="patent-data-table-td ">Cooperative Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=805ABAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C12N9/1252">C12N9/1252</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=805ABAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C12Q1/686">C12Q1/686</a></span></td></tr><tr><td class="patent-data-table-td ">European Classification</td><td class="patent-data-table-td "><span class="nested-value">C12N9/12J7</span>, <span class="nested-value">C12Q1/68D4</span></td></tr></table><div class="patent-section-footer"></div></div><div class="patent-section patent-tabular-section"><a id="legal-events"></a><div class="patent-section-header"><span class="patent-section-title">Legal Events</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Date</th><th class="patent-data-table-th">Code</th><th class="patent-data-table-th">Event</th><th class="patent-data-table-th">Description</th></tr></thead><tr><td class="patent-data-table-td patent-date-value">Jul 6, 2010</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20100615</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">AGILENT TECHNOLOGIES, INC.,COLORADO</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:STRATAGENE CALIFORNIA;REEL/FRAME:24630/870</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:STRATAGENE CALIFORNIA;REEL/FRAME:024630/0870</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">AGILENT TECHNOLOGIES, INC., COLORADO</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jan 6, 2009</td><td class="patent-data-table-td ">B1</td><td class="patent-data-table-td ">Reexamination certificate first reexamination</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">THE PATENTABILITY OF CLAIMS 3-7 IS CONFIRMED. CLAIM 1 IS DETERMINED TO BE PATENTABLE AS AMENDED. CLAIMS 2 AND 8-13, DEPENDENT ON AN AMENDED CLAIM, ARE DETERMINED TO BE PATENTABLE.</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Dec 10, 2008</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">STRATEGENE CALIFORNIA, CALIFORNIA</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">RELEASE BY SECURED PARTY;ASSIGNOR:MERRILL LYNCH BUSINESS FINANCIAL SERVICES, INC.;REEL/FRAME:021952/0174</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20081030</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Feb 21, 2008</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">12</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jan 20, 2005</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">STRATAGENE CALIFORNIA, CALIFORNIA</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">CHANGE OF NAME;ASSIGNOR:STRATAGENE;REEL/FRAME:016172/0417</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20031209</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">STRATAGENE CALIFORNIA 11011 N. TORREY PINES ROADLA</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">CHANGE OF NAME;ASSIGNOR:STRATAGENE /AR;REEL/FRAME:016172/0417</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">May 18, 2004</td><td class="patent-data-table-td ">RR</td><td class="patent-data-table-td ">Request for reexamination filed</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20040409</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Mar 17, 2004</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">8</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Feb 9, 2004</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">TCW SPECIAL CREDITS FUND V - THE, CALIFORNIA</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">SECURITY AGREEMENT;ASSIGNOR:STRATAGENE CALIFORNIA, FORMERLY KNOWN AS STRATAGENE;REEL/FRAME:014981/0660</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20040203</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">TCW SPECIAL CREDITS FUND V - THE PRINCIPAL FUND -</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">SECURITY AGREEMENT;ASSIGNOR:STRATAGENE CALIFORNIA, FORMERLY KNOWN AS STRATAGENE /AR;REEL/FRAME:014981/0660</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Feb 6, 2004</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">TCW SPECIAL CREDITS FUND V-THE PRINCIPAL FUND C/O</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">SECURITY AGREEMENT;ASSIGNOR:STRATAGENE CALIFORNIA, FORMERLY KNOWN AS STRATAGENE;REEL/FRAME:014981/0654</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20040203</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">SECURITY AGREEMENT;ASSIGNOR:STRATAGENE CALIFORNIA, FORMERLY KNOWN AS STRATAGENE /AR;REEL/FRAME:014981/0654</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Feb 4, 2004</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">MERILL LYNCH BUSINESS FINANCIAL SERVICES INC., ILL</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">SECURITY AGREEMENT;ASSIGNOR:STRATAGENE CALIFORNIA;REEL/FRAME:015167/0632</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20040121</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">MERILL LYNCH BUSINESS FINANCIAL SERVICES INC. 222</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">SECURITY AGREEMENT;ASSIGNOR:STRATAGENE CALIFORNIA /AR;REEL/FRAME:015167/0632</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">MERRILL LYNCH BUSINESS FINANCIAL SERVICES INC. 222</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">A CORRECTIVE SECURITY AGREEMENT TO CORRECT THE ASSIGNOR ON REEL 014926 FRAME 0078;ASSIGNOR:STRATAGENE CALIFORNIA /AR;REEL/FRAME:014943/0500</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jan 29, 2004</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">STRATAGENE, CALIFORNIA</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:UNION BANK OF CALIFORNIA, N.A.;REEL/FRAME:014885/0317</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20040115</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">RELEASE OF PATENTS COLLATERAL;ASSIGNOR:UNION BANK OF CALIFORNIA, N.A.;REEL/FRAME:014918/0364</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20040123</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">STRATAGENE 11011 N. TORREY PINES ROADLA JOLLA, CAL</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:UNION BANK OF CALIFORNIA, N.A. /AR;REEL/FRAME:014885/0317</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">RELEASE OF PATENTS COLLATERAL;ASSIGNOR:UNION BANK OF CALIFORNIA, N.A. /AR;REEL/FRAME:014918/0364</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jan 26, 2004</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">MERRILL LYNCH BUSINESS FINANCIAL SERVICES INC., IL</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">SECURITY INTEREST;ASSIGNOR:STRATAGENE CORPORATION;REEL/FRAME:014926/0078</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20040121</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">MERRILL LYNCH BUSINESS FINANCIAL SERVICES INC. 222</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">SECURITY INTEREST;ASSIGNOR:STRATAGENE CORPORATION /AR;REEL/FRAME:014926/0078</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jun 16, 2003</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">TAKARA BIO INC., JAPAN</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TAKARA SHUZO CO., LTD.;REEL/FRAME:014172/0065</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20030613</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">TAKARA SHUZO CO., LTD., JAPAN</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BARNES, WAYNE M.;REEL/FRAME:014845/0714</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20030424</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">TAKARA BIO INC. SETA 3-4-1OTSU, SHIGA 520-2193, (1</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jun 5, 2003</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">TAKARA BIO INC., JAPAN</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BARNES, WAYNE M.;REEL/FRAME:014128/0450</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20030422</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">TAKARA BIO INC. SETA 3-4-1OTSU, SHIGA 520-2193, (1</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jun 2, 2003</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">TAKARA BIO INC., JAPAN</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TAKARA HOLDINGS INC. (FORMERLY SHUZO CO., LTD.);REEL/FRAME:014770/0806</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20030328</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Apr 22, 2003</td><td class="patent-data-table-td ">RR</td><td class="patent-data-table-td ">Request for reexamination filed</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20030320</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jun 18, 2002</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">UNION BANK OF CALIFORNIA, N.A., CALIFORNIA</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">SECURITY AGREEMENT;ASSIGNOR:STRATAGENE;REEL/FRAME:013000/0453</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20020328</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">UNION BANK OF CALIFORNIA, N.A. 530 B STREET SAN DI</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">UNION BANK OF CALIFORNIA, N.A. 530 B STREETSAN DIE</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">SECURITY AGREEMENT;ASSIGNOR:STRATAGENE /AR;REEL/FRAME:013000/0453</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Feb 11, 2000</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">4</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jun 10, 1996</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">UNION BANK OF CALIFORNIA, N.A., CALIFORNIA</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:UNION BANK;REEL/FRAME:007991/0247</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">19960401</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jan 22, 1996</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">UNION BANK, CALIFORNIA</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">SECURITY INTEREST;ASSIGNOR:STRATAGENE;REEL/FRAME:007837/0408</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">19951201</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Aug 5, 1994</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">STRATAGENE, CALIFORNIA</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SORGE, JOSEPH A.;MULLINAX, REBECCA LYNN;REEL/FRAME:007250/0923;SIGNING DATES FROM 19940613 TO 19940620</span></div></td></tr></table><div class="patent-section-footer"></div></div><div class="modal-dialog" id="patent-images-lightbox"><div class="patent-lightbox-controls"><div class="patent-lightbox-rotate-controls"><div class="patent-lightbox-rotation-text">Rotate</div><div class="rotate-icon rotate-ccw-icon"></div><div class="rotate-icon rotate-cw-icon"></div></div><div class="patent-lightbox-index-counter"></div><a class="patent-lightbox-fullsize-link" target="_blank">Original Image</a><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_right.png" alt="Next page"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_left.png" alt="Previous page"width="21" height="21" /></div></div><div class="modal-dialog-content"><div class="patent-lightbox-image-holder"><div class="patent-lightbox-placeholder"></div></div></div></div><script>_OC_initPatentsAtb({image_not_available_html: " Image not available"});</script></div></div></div></td></tr></table><script>(function() {var href = window.location.href;if (href.indexOf('?') !== -1) {var parameters = href.split('?')[1].split('&');for (var i = 0; i < parameters.length; i++) {var param = parameters[i].split('=');if (param[0] == 'focus') {var elem = document.getElementById(param[1]);if (elem) {elem.focus();}}}}})();</script><script>_OC_addFlags({LockSrc:"/books/javascript/lock_8a2b04e7bf975d5171d8e4c0b6365c7a.js", Host:"http://www.google.com/", IsBooksRentalEnabled:1, IsWebstoreDisplayCaseEnabled:1, IsObfuscationEnabled:1, IsBrowsingHistoryEnabled:1, IsWebReaderSvgEnabled:0, IsGeoLayerEnabled:1, IsImageModeNotesEnabled:1, IsCopyMenuItemEnabled:1, IsGiftingEnabled:0, IsWebReaderUniversalPaginatorEnabled:0, IsOfflineBubbleEnabled:1, IsReaderEnabledForPlayRequests:1, IsFutureOnSaleVolumesEnabled:1, IsOfflineRestrictedCopyEnabled:1, IsBooksUnifiedLeftNavEnabled:1, IsRestrictedCopyEnabled:1, IsZipitFolderCollectionEnabled:1, IsEndOfSampleRecommendationsEnabled:1, IsRatingsOnBookcardsEnabled:1, IsAdsDisabled:0, IsIframePageDisplayEnabled:0, IsEmbeddedMediaEnabled:1, IsImageModeAnnotationsEnabled:1, IsMyLibraryGooglePlusEnabled:1, IsImagePageProviderEnabled:0, IsBookcardListPriceSmall:0, IsInternalUser:0, IsBooksShareButtonEnabled:0, IsPreOrdersEnabled:0, IsDisabledRandomBookshelves:0, WebstoreDisplayCasePosition:3});_OC_Run({"enable_p13n":false,"add_vol_to_collection_base_url":"http://www.google.com/patents?op=add\u0026sig=ACfU3U3NFz0DC0ed_XCLmS9TeY9RFJZ3Gw\u0026id=805ABAABERAJ","remove_vol_from_collection_base_url":"http://www.google.com/patents?op=remove\u0026sig=ACfU3U38oqe2DURL4yFiQO1QjVOQGBTy5A\u0026id=805ABAABERAJ","logged_in":false,"p13n_save_user_settings_url":"http://www.google.com/patents?op=edit_user_settings\u0026sig=ACfU3U2jRKECKKBJBNDiZKAJjM1TK3j5lQ","is_cobrand":false,"sign_in_url":"https://www.google.com/accounts/Login?service=\u0026continue=http://www.google.com/patents%3Fhl%3Den\u0026hl=en","is_play_enabled":true}, {"volume_id":"","is_ebook":true,"volumeresult":{"has_flowing_text":false,"has_scanned_text":true,"can_download_pdf":false,"can_download_epub":false,"is_pdf_drm_enabled":false,"is_epub_drm_enabled":false,"download_pdf_url":"http://www.google.com/patents/download/Polymerase_compositions_and_uses_thereof.pdf?id=805ABAABERAJ\u0026output=pdf\u0026sig=ACfU3U2q1-Th9OoEgZtfTqTxHeWgHE07UA"},"sample_url":"http://www.google.com/patents/reader?id=805ABAABERAJ\u0026printsec=frontcover\u0026output=reader\u0026source=gbs_atb_hover","is_browsable":true,"is_public_domain":true}, {});</script><div id="footer_table" style="font-size:83%;text-align:center;position:relative;top:20px;height:4.5em;margin-top:2em"><div style="margin-bottom:8px"><a href=http://www.google.com/><nobr>Google&nbsp;Home</nobr></a> - <a href=//www.google.com/patents/sitemap/><nobr>Sitemap</nobr></a> - <a href=http://www.google.com/googlebooks/uspto.html><nobr>USPTO Bulk Downloads</nobr></a> - <a href=/intl/en/privacy/><nobr>Privacy Policy</nobr></a> - <a href=/intl/en/policies/terms/><nobr>Terms of Service</nobr></a> - <a href=https://support.google.com/faqs/answer/2539193?hl=en><nobr>About Google Patents</nobr></a> - <a href="http://www.google.com/tools/feedback/intl/en/error.html" onclick="try{_OC_startFeedback({productId: '72792',locale: 'en'});return false;}catch(e){}"><nobr>Send Feedback</nobr></a></div><span>Data provided by IFI CLAIMS Patent Services</span><br><span >&copy;2012 Google</span></div> <script type="text/javascript">var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));</script><script type="text/javascript">var pageTracker = _gat._getTracker("UA-27188110-1");pageTracker._setCookiePath("/patents/");pageTracker._trackPageview();</script> </body></html>